

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87980 A2(51) International Patent Classification⁷: C07K 14/705,
C12N 15/12, C07K 16/28, A01K 67/027, A61K 38/17

(21) International Application Number: PCT/US01/15957

(22) International Filing Date: 17 May 2001 (17.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/205,196 18 May 2000 (18.05.2000) US
09/634,656 8 August 2000 (08.08.2000) US(71) Applicant: APPLERA CORPORATION [US/US];
Robert A. Millman, Assistant Secretary, 761 Main Avenue,
Norwalk, CT 06859 (US).(72) Inventors: WEI, Ming-Hui; Celera, 45 West Gude Drive,
Rockville, MD 20850 (US). ZHAO, Qi; Celera, 45 WestGude Drive, Rockville, MD 20850 (US). CRAVCHIK,
Anibal; Celera, 45 West Gude Drive, Rockville, MD 20850
(US). DI FRANCESCO, Valentina; Celera, 45 West Gude
Drive, Rockville, MD 20850 (US). BEASLEY, Ellen M.;
Celera, 45 West Gude Drive, Rockville, MD 20850 (US).(74) Agent: CELERA GENOMICS CORP.; Robert A. Mill-
man, Patent Director, 45 West Gude Drive C2-4, Rockville,
MD 20850 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN
GPCR PROTEINS, AND USES THEREOF

```

1  ATGAATGAGC  CACTAGACTA  TTTAGCAAAT  GCTTCTGATT  TCCCGGATTA
51  TGCAGCTGCT  TTTGGAATTT  GCACATGATG  AAACATCCCA  CTCAGATGCG
101  ACTACCTGCC  TGTATTATTT  GGCATTATCT  TCCTCGTGCG  ATTTCCAGGC
151  AATGCACTAG  TGATATCCAC  TTACATTTTC  AAAATGAGAC  CTGGAAGAG
201  CAGCACCATC  ATTATGCTGA  ACCTGGCCTG  CACAGACTCG  CTGTATCTGA
251  CCAGCTCCCG  CTTCCTGATT  CACTACTATG  CCAGTGGCGA  AAATCGGATC
301  TTTGAGATT  TCATGTGTAA  GTTTATCCGC  TTCAGCTTCC  ATTTCAACCT
351  GTATAGCAGC  ATCCTCTTCC  TCACCTGTTC  CAGCATCTTC  CGCTACTGTG
401  TGATCATTCA  CCCAATGAGC  TGCTTTTCCA  TTCACAAAAC  TCGATGTGCA
451  GTTGTAGCCT  GTGCTGTGGT  GTGGATCATT  TCACCTGGTAG  CTGTCAATTC
501  GATGACCTTC  TTGATCAGAT  CAACCAACAG  GACCAACAGA  TCAGCCTGTC
551  TCGACCTCAC  CAGTTCGGAT  GAACTCAATA  CTATTAAGTG  GTACAACCTC
601  ATTTGACTG  CACTACTTTT  CTGCCTCCCC  TTGGTGATAG  TGACACTTTG
651  CTATACCAGC  ATTATCCACA  CTCTGACCCA  TGGACTGCAA  ACTGACAGCT
701  GCCTTAAGCA  GAAAGCAGCA  AGGCTAACCA  TTCTGCTACT  CCTTGCATTT
751  TACGTATGTT  TTTTACCCCT  CCATATCTTG  AGGCTCATTC  GGATCGAATC
801  TCGCCTGCTT  TCAATCAGTT  GTTCCATTGA  GAATCAGATC  CATGAAGCTT
851  ACATCGTTTC  TAGACCATTA  GCTGCTCTGA  ACACCTTTGG  TAACCTGTTA
901  CTATATGTGG  TGGTCAGCGA  CAACCTTCAG  CAGGCTGTCT  GCTCAACAGT
951  GAGATGCAAA  GTAAGCGGGA  ACCTTGAGCA  AGCAAAGAAA  ATTAGTTACT
1001  CAAACAACCC  TTGA

```

FEATURES:
Start: 1
Stop: 1012

HOMOLOGOUS PROTEIN:

```

gi16679193|ref|NP_032798.1| purinergic receptor P2Y, G-protein ... 226 2e-58
gi14505557|ref|NP_002554.1| purinergic receptor P2Y, G-protein ... 223 2e-57
gi11352695|sp|P49651|P2YR_RAT P2Y PURINOCEPTOR 1 (ATP RECEPTOR)... 222 3e-57
gi14643271|sp|P34996|P2YR_CHICK P2Y PURINOCEPTOR 1 (ATP RECEPTOR)... 221 7e-57
gi11352693|sp|P49652|P2YR_MELGA P2Y PURINOCEPTOR 1 (ATP RECEPTOR)... 221 7e-57
gi11352691|sp|P48042|P2YR_BOVIN P2Y PURINOCEPTOR 1 (ATP RECEPTOR)... 221 7e-57
gi11082756|pir|I554253 purinergic receptor - human >gi1798836|e... 217 1e-55
gi12829680|sp|P79928|P2Y8_XENLA P2Y PURINOCEPTOR 8 (P2Y8) >gi1... 217 2e-55
gi12707256|gb|AAC60339.1| (AF031897) G protein coupled P2Y nucl... 215 7e-55

```

blast to dbEST:

```

gi17921097|gb|AW827323.1|AW827323 hm31f01.x1 NCI_CGAP_Thy4 Homo... 46 0.022
gi12900654|gb|AA826657.1|AA826657 of34e08.s1 NCI_CGAP_Kid6 Homo... 42 0.35

```

Expression information for modulatory use (from cDNA panel screening):

Human uterus
Human Placenta
Human Brain
Human Fetal Brain

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the Human genome, the GPCR peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the GPCR peptides and methods of identifying modulators of the GPCR peptides.

WO 01/87980 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR PROTEINS, AND USES THEREOF

RELATED APPLICATIONS

5 The present application claims priority to U.S. Serial No. 09/634,656, filed August 8, 2000 (Atty. Docket CL000750) and U.S. Serial No. 60/205,196, filed May 18, 2000 (Atty. Docket CL000567-PROV).

FIELD OF THE INVENTION

10 The present invention is in the field of G-Protein coupled receptors (GPCRs) that are related to the purinergic receptor subfamily, recombinant DNA molecules and protein production. The present invention specifically provides novel GPCR peptides and proteins and nucleic acid molecules encoding such protein molecules, for use in the development of human therapeutics and human therapeutic development.

15 BACKGROUND OF THE INVENTION

G-protein coupled receptors

 G-protein coupled receptors (GPCRs) constitute a major class of proteins responsible for transducing a signal within a cell. GPCRs have three structural domains: an amino terminal extracellular domain, a transmembrane domain containing seven transmembrane segments, three
20 extracellular loops, and three intracellular loops, and a carboxy terminal intracellular domain. Upon binding of a ligand to an extracellular portion of a GPCR, a signal is transduced within the cell that results in a change in a biological or physiological property of the cell. GPCRs, along with G-proteins and effectors (intracellular enzymes and channels modulated by G-proteins), are the components of a modular signaling system that connects the state of intracellular second messengers to extracellular
25 inputs.

 GPCR genes and gene-products are potential causative agents of disease (Spiegel *et al.*, *J. Clin. Invest.* 92:1119-1125 (1993); McKusick *et al.*, *J. Med. Genet.* 30:1-26 (1993)). Specific defects in the rhodopsin gene and the V2 vasopressin receptor gene have been shown to cause various forms of retinitis pigmentosum (Nathans *et al.*, *Annu. Rev. Genet.* 26:403-424(1992)), and nephrogenic diabetes
30 insipidus (Holtzman *et al.*, *Hum. Mol. Genet.* 2:1201-1204 (1993)). These receptors are of critical importance to both the central nervous system and peripheral physiological processes. Evolutionary

analyses suggest that the ancestor of these proteins originally developed in concert with complex body plans and nervous systems.

The GPCR protein superfamily can be divided into five families: Family I, receptors typified by rhodopsin and the β 2-purineric receptor and currently represented by over 200 unique members
5 (Dohlman *et al.*, *Annu. Rev. Biochem.* 60:653-688 (1991)); Family II, the parathyroid hormone/calcitonin/secretin receptor family (Juppner *et al.*, *Science* 254:1024-1026 (1991); Lin *et al.*, *Science* 254:1022-1024 (1991)); Family III, the metabotropic glutamate receptor family (Nakanishi, *Science* 258 597:603 (1992)); Family IV, the cAMP receptor family, important in the chemotaxis and development of *D. discoideum* (Klein *et al.*, *Science* 241:1467-1472 (1988)); and Family V, the fungal
10 mating pheromone receptors such as STE2 (Kurjan, *Annu. Rev. Biochem.* 61:1097-1129 (1992)).

There are also a small number of other proteins that present seven putative hydrophobic segments and appear to be unrelated to GPCRs; they have not been shown to couple to G-proteins. *Drosophila* expresses a photoreceptor-specific protein, bride of sevenless (boss), a seven-transmembrane-segment protein that has been extensively studied and does not show evidence of being
15 a GPCR (Hart *et al.*, *Proc. Natl. Acad. Sci. USA* 90:5047-5051 (1993)). The gene *frizzled* (*fz*) in *Drosophila* is also thought to be a protein with seven transmembrane segments. Like boss, *fz* has not been shown to couple to G-proteins (Vinson *et al.*, *Nature* 338:263-264 (1989)).

G proteins represent a family of heterotrimeric proteins composed of α , β and γ subunits, that bind guanine nucleotides. These proteins are usually linked to cell surface receptors, e.g., receptors
20 containing seven transmembrane segments. Following ligand binding to the GPCR, a conformational change is transmitted to the G protein, which causes the α -subunit to exchange a bound GDP molecule for a GTP molecule and to dissociate from the $\beta\gamma$ -subunits. The GTP-bound form of the α -subunit typically functions as an effector-modulating moiety, leading to the production of second messengers, such as cAMP (e.g., by activation of adenylyl cyclase), diacylglycerol or inositol phosphates. Greater
25 than 20 different types of α -subunits are known in humans. These subunits associate with a smaller pool of β and γ subunits. Examples of mammalian G proteins include Gi, Go, Gq, Gs and Gt. G proteins are described extensively in Lodish *et al.*, *Molecular Cell Biology*, (Scientific American Books Inc., New York, N.Y., 1995), the contents of which are incorporated herein by reference. GPCRs, G proteins and G protein-linked effector and second messenger systems have been reviewed
30 in *The G-Protein Linked Receptor Fact Book*, Watson *et al.*, eds., Academic Press (1994).

Purinergic GPCRs

Purinoceptor P2Y1

P2 purinoceptors have been broadly classified as P2X receptors which are ATP-gated channels; P2Y receptors, a family of G protein-coupled receptors, and P2Z receptors, which mediate
5 nonselective pores in mast cells. Numerous subtypes have been identified for each of the P2 receptor classes. P2Y receptors are characterized by their selective responsiveness towards ATP and its analogs. Some respond also to UTP. Based on the recommendation for nomenclature of P2 purinoceptors, the P2Y purinoceptors were numbered in the order of cloning. P2Y1, P2Y2 and P2Y3 have been cloned from a variety of species. P2Y1 responds to both ADP and ATP. Analysis of P2Y
10 receptor subtype expression in human bone and 2 osteoblastic cell lines by RT-PCR showed that all known human P2Y receptor subtypes were expressed: P2Y1, P2Y2, P2Y4, P2Y6, and P2Y7 (Maier et al. 1997). In contrast, analysis of brain-derived cell lines suggested that a selective expression of P2Y receptor subtypes occurs in brain tissue.

Leon et al. generated P2Y1-null mice to define the physiologic role of the P2Y1 receptor. (J.
15 Clin. Invest. 104: 1731-1737(1999)) These mice were viable with no apparent abnormalities affecting their development, survival, reproduction, or morphology of platelets, and the platelet count in these animals was identical to that of wildtype mice. However, platelets from P2Y1-deficient mice were unable to aggregate in response to usual concentrations of ADP and displayed impaired aggregation to other agonists, while high concentrations of ADP induced platelet aggregation without shape change.
20 In addition, ADP-induced inhibition of adenylyl cyclase still occurred, demonstrating the existence of an ADP receptor distinct from P2Y1. P2Y1-null mice had no spontaneous bleeding tendency but were resistant to thromboembolism induced by intravenous injection of ADP or collagen and adrenaline. Hence, the P2Y1 receptor plays an essential role in thrombotic states and represents a potential target for antithrombotic drugs. Somers et al. mapped the P2RY1 gene between flanking markers D3S1279 and D3S1280 at a position 173 to 174 cM from the most telomeric markers on the short arm of
25 chromosome 3. (Genomics 44: 127-130 (1997)).

Purinoceptor P2Y2

The chloride ion secretory pathway that is defective in cystic fibrosis (CF) can be bypassed by an alternative pathway for chloride ion transport that is activated by extracellular nucleotides.
30 Accordingly, the P2 receptor that mediates this effect is a therapeutic target for improving chloride secretion in CF patients. Parr et al. reported the sequence and functional expression of a cDNA cloned from human airway epithelial cells that encodes a protein with properties of a P2Y nucleotide receptor. (Proc. Nat. Acad. Sci. 91: 3275-3279 (1994)) The human P2RY2 gene was mapped to chromosome 11q13.5-q14.1.

Purinoreceptor P2RY4

The P2RY4 receptor appears to be activated specifically by UTP and UDP, but not by ATP and ADP. Activation of this uridine nucleotide receptor resulted in increased inositol phosphate formation and calcium mobilization. The UNR gene is located on chromosome Xq13.

5 Purinoreceptor P2Y6

Somers et al. mapped the P2RY6 gene to 11q13.5, between polymorphic markers D11S1314 and D11S916, and P2RY2 maps within less than 4 cM of P2RY6. (Genomics 44: 127-130 (1997)) This was the first chromosomal clustering of this gene family to be described.

10 Adenine and uridine nucleotides, in addition to their well established role in intracellular energy metabolism, phosphorylation, and nucleic acid synthesis, also are important extracellular signaling molecules. P2Y metabotropic receptors are GPCRs that mediate the effects of extracellular nucleotides to regulate a wide variety of physiological processes. At least ten subfamilies of P2Y receptors have been identified. These receptor subfamilies differ greatly in their sequences and in their nucleotide agonist selectivities and efficacies.

15 It has been demonstrated that the P2Y1 receptors are strongly expressed in the brain, but the P2Y2, P2Y4 and P2Y6 receptors are also present. The localisation of one or more of these subtypes on neurons, on glia cells, on brain vasculature or on ventricle ependymal cells was found by in situ mRNA hybridisation and studies on those cells in culture. The P2Y1 receptors are prominent on neurons. The coupling of certain P2Y receptor subtypes to N-type Ca²⁺ channels or to particular K⁺ channels was
20 also demonstrated.

It has also been demonstrated that several P2Y receptors mediate potent growth stimulatory effects on smooth muscle cells by stimulating intracellular pathways including Gq-proteins, protein kinase C and tyrosine phosphorylation, leading to increased immediate early gene expression, cell number, DNA and protein synthesis. It has been further demonstrated that P2Y regulation plays a
25 mitogenic role in response to the development of atherosclerosis.

It has further been demonstrated that P2Y receptors play a critical role in cystic fibrosis. The volume and composition of the liquid that lines the airway surface is modulated by active transport of ions across the airway epithelium. This in turn is regulated both by autonomic agonists acting on basolateral receptors and by agonists acting on luminal receptors. Specifically, extracellular
30 nucleotides present in the airway surface liquid act on luminal P2Y receptors to control both Cl⁻ secretion and Na⁺ absorption. Since nucleotides are released in a regulated manner from airway epithelial cells, it is likely that their control over airway ion transport forms part of an autocrine regulatory system localised to the luminal surface of airway epithelia. In addition to this physiological

role, P2Y receptor agonists have the potential to be of crucial benefit in the treatment of CF, a disorder of epithelial ion transport. The airways of people with CF have defective Cl⁻ secretion and abnormally high rates of Na⁺ absorption. Since P2Y receptor agonists can regulate both these ion transport pathways they have the potential to pharmacologically bypass the ion transport defects in CF.

5 GPCRs, particularly members of the purinergic receptor subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown GPCRs. The present invention advances the state of the art by providing a previously unidentified human GPCR.

10 SUMMARY OF THE INVENTION

The present invention is based in part on the identification of nucleic acid sequences that encode amino acid sequences of human GPCR peptides and proteins that are related to the purinergic subfamily, allelic variants thereof and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for
15 the development of human therapeutic targets, aid in the identification of therapeutic proteins and serve as targets for the development of human therapeutic agents.

The proteins of the present inventions are GPCRs that participate in signaling pathways mediated by the purinergic subfamily in cells that express these proteins (see expression information in Figure 1, the GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as
20 determined by cDNA panel screening). As used herein, a "signaling pathway" refers to the modulation (e.g., stimulation or inhibition) of a cellular function/activity upon the binding of a ligand to the GPCR protein. Examples of such functions include mobilization of intracellular molecules that participate in a signal transduction pathway, e.g., phosphatidylinositol 4,5-bisphosphate (PIP₂), inositol 1,4,5-triphosphate (IP₃) and adenylate cyclase; polarization of the plasma membrane; production or secretion
25 of molecules; alteration in the structure of a cellular component; cell proliferation, e.g., synthesis of DNA; cell migration; cell differentiation; and cell survival

The response mediated by the receptor protein depends on the type of cell it is expressed on. Some information regarding the types of cells that express other members of the subfamily of GPCRs of the present invention is already known in the art (see references cited in Background and
30 information regarding closest homologous protein provided in Figure 2 and expression information provided in Figure 1, the GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). For example, in some cells, binding of a ligand to the receptor protein may stimulate an activity such as release of compounds, gating of a channel, cellular adhesion, migration, differentiation, etc., through phosphatidylinositol or cyclic AMP

metabolism and turnover while in other cells, the binding of the ligand will produce a different result. Regardless of the cellular activity/response modulated by the particular GPCR of the present invention, a skilled artisan will clearly know that the receptor protein is a GPCR and interacts with G proteins to produce one or more secondary signals, in a variety of intracellular signal transduction pathways, e.g., through phosphatidylinositol or cyclic AMP metabolism and turnover, in a cell thus participating in a biological process in the cells or tissues that express the GPCR (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

As used herein, "phosphatidylinositol turnover and metabolism" refers to the molecules involved in the turnover and metabolism of phosphatidylinositol 4,5-bisphosphate (PIP₂) as well as to the activities of these molecules. PIP₂ is a phospholipid found in the cytosolic leaflet of the plasma membrane. Binding of ligand to the receptor activates, in some cells, the plasma-membrane enzyme phospholipase C that in turn can hydrolyze PIP₂ to produce 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP₃). Once formed IP₃ can diffuse to the endoplasmic reticulum surface where it can bind an IP₃ receptor, e.g., a calcium channel protein containing an IP₃ binding site. IP₃ binding can induce opening of the channel, allowing calcium ions to be released into the cytoplasm. IP₃ can also be phosphorylated by a specific kinase to form inositol 1,3,4,5-tetraphosphate (IP₄), a molecule that can cause calcium entry into the cytoplasm from the extracellular medium. IP₃ and IP₄ can subsequently be hydrolyzed very rapidly to the inactive products inositol 1,4-bisphosphate (IP₂) and inositol 1,3,4-triphosphate, respectively. These inactive products can be recycled by the cell to synthesize PIP₂. The other second messenger produced by the hydrolysis of PIP₂, namely 1,2-diacylglycerol (DAG), remains in the cell membrane where it can serve to activate the enzyme protein kinase C. Protein kinase C is usually found soluble in the cytoplasm of the cell, but upon an increase in the intracellular calcium concentration, this enzyme can move to the plasma membrane where it can be activated by DAG. The activation of protein kinase C in different cells results in various cellular responses such as the phosphorylation of glycogen synthase, or the phosphorylation of various transcription factors, e.g., NF-kB. The language "phosphatidylinositol activity", as used herein, refers to an activity of PIP₂ or one of its metabolites.

Another signaling pathway in which the receptor may participate is the cAMP turnover pathway. As used herein, "cyclic AMP turnover and metabolism" refers to the molecules involved in the turnover and metabolism of cyclic AMP (cAMP) as well as to the activities of these molecules. Cyclic AMP is a second messenger produced in response to ligand-induced stimulation of certain G protein coupled receptors. In the cAMP signaling pathway, binding of a ligand to a GPCR can lead to the activation of the enzyme adenylyl cyclase, which catalyzes the synthesis of cAMP. The newly synthesized cAMP can in turn activate a cAMP-dependent protein kinase. This

activated kinase can phosphorylate a voltage-gated potassium channel protein, or an associated protein, and lead to the inability of the potassium channel to open during an action potential. The inability of the potassium channel to open results in a decrease in the outward flow of potassium, which normally repolarizes the membrane of a neuron, leading to prolonged membrane depolarization.

By targeting an agent to modulate a GPCR, the signaling activity and biological process mediated by the receptor can be agonized or antagonized in specific cells and tissues (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Such agonism and antagonism serves as a basis for modulating a biological activity in a therapeutic context (mammalian therapy) or toxic context (anti-cell therapy, e.g. anti-cancer agent).

DESCRIPTION OF THE FIGURE SHEETS

FIGURE 1 provides the nucleotide sequence of a cDNA molecule or transcript sequence that encodes the GPCR of the present invention. In addition structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

FIGURE 2 provides the predicted amino acid sequence of the GPCR of the present invention. In addition structure and functional information, such as protein family and function, modification sites, is provided that allows one to readily determine specific uses of inventions based on this molecular sequence as well as significant fragments of the proteins of the present invention.

FIGURE 3 provides genomic sequences that span the gene encoding the GPCR protein of the present invention. In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided that allows one to readily determine specific uses of inventions based on this molecular sequence as well as important fragments for use in probe and primer design and heterologous gene expression control. Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a GPCR protein or part of a GPCR protein, that are related to the purinergic subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human GPCR peptides and proteins, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these GPCR peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the GPCR of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known GPCR proteins of the purinergic subfamily and the expression pattern observed (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the know purinergic family or subfamily of GPCR proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the GPCR family of proteins (protein sequences are provided in Figure 2, transcript/cDNA sequences are provided in Figures 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious

variants described herein, such as allelic variants, will be referred herein as the GPCR peptides of the present invention, GPCR peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of or are comprised of the amino acid sequences of the GPCR peptides disclosed
5 in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, transcript/cDNA and Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present
10 invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide
15 having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes
20 preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the GPCR peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5%
25 chemical precursors or other chemicals.

The isolated GPCR peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). For example, a nucleic acid molecule encoding the GPCR
30 peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequences that such a protein consists of is provided in Figure 2. A
5 protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in
10 Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that are comprised of the amino acid sequences provided in Figure 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NO:1) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein is comprised of an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded
20 sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the GPCR peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

25 The GPCR peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a GPCR peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the GPCR peptide. "Operatively linked" indicates that the GPCR peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the GPCR
30 peptide.

In some uses, the fusion protein does not affect the activity of the GPCR peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of

recombinant GPCR peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A GPCR peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the GPCR peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art know techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the GPCR peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at

that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

- 5 The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994;
- 10 *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at
- 15 <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50,
- 20 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- 25 The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to
- 30 obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (*Nucleic*

Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence
5 identity to one of the GPCR peptides of the present invention as well as being encoded by the same genetic locus as the GPCR peptide provided herein. The GPCR of the present invention is encoded by a gene on chromosome 13 near markers SHGC-68276 (LOD=8.71) and SHGC-8118 (LOD=7.82).

Allelic variants of a GPCR peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the GPCR peptide as
10 well as being encoded by the same genetic locus as the GPCR peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human (The GPCR of the present invention is encoded by a gene on chromosome 13 near markers SHGC-68276 (LOD=8.71) and SHGC-8118 (LOD=7.82)). As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid
15 sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides SNP information that has been found in the gene encoding the GPCR
20 proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.

Paralogs of a GPCR peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the GPCR peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered
25 paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a GPCR peptide can readily be identified as having some degree of significant
30 sequence homology/identity to at least a portion of the GPCR peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a GPCR peptide encoding nucleic acid molecule under

moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the GPCR peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the GPCR peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a GPCR peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant GPCR peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind ligand, ability to bind G-protein, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis that identifies critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as ligand/effector molecule binding or in assays such as an *in vitro* proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the GPCR peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly fragments identified in Figure 2.

The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16 or more contiguous amino acid residues from a GPCR peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the GPCR peptide or could be chosen for the ability to perform a function, e.g. ability to bind ligand or effector molecule or act as an immunogen. Particularly important fragments are biologically active fragments, peptides which are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the GPCR peptide, e.g., active site, a G-protein binding site, a transmembrane domain or a ligand-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well-known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in GPCR peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Accordingly, the GPCR peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature GPCR peptide is fused with another compound, such as a compound to increase the half-life of the GPCR peptide (for example, polyethylene glycol),

or in which the additional amino acids are fused to the mature GPCR peptide, such as a leader or secretory sequence or a sequence for purification of the mature GPCR peptide or a pro-protein sequence.

Such modifications are well-known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures and Back Ground Section; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or receptor) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the binding partner so as to develop a system to identify inhibitors of the binding interaction. Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, GPCRs isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug to modulate the cells or tissues that express the receptor (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Approximately 70% of all pharmaceutical agents modulate

the activity of a GPCR. A combination of the invertebrate and mammalian ortholog can be used in selective screening methods to find agents specific for invertebrates. The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention. Such uses can readily be determined using the information
5 provided herein, that known in the art and routine experimentation.

The receptor polypeptides (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to GPCRs. Such assays involve any of the known GPCR functions or activities or properties useful for diagnosis and treatment of GPCR-related conditions that are specific for the subfamily of GPCRs that the one of the present invention
10 belongs to, particularly in cells and tissues that express this receptor (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

The receptor polypeptides are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the receptor protein, as a
15 biopsy or expanded in cell culture (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). In one embodiment, however, cell-based assays involve recombinant host cells expressing the receptor protein.

The polypeptides can be used to identify compounds that modulate receptor activity of the protein in its natural state, or an altered form that causes a specific disease or pathology associated with
20 the receptor. Both the GPCRs of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the receptor. These compounds can be further screened against a functional receptor to determine the effect of the compound on the receptor activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or
25 inactivate (antagonist) the receptor to a desired degree.

Further, the receptor polypeptides can be used to screen a compound for the ability to stimulate or inhibit interaction between the receptor protein and a molecule that normally interacts with the receptor protein, e.g. a ligand or a component of the signal pathway that the receptor protein normally interacts (for example, a G-protein or other interactor involved in cAMP or phosphatidylinositol
30 turnover and/or adenylate cyclase, or phospholipase C activation). Such assays typically include the steps of combining the receptor protein with a candidate compound under conditions that allow the receptor protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the receptor protein and the target, such as any of the associated effects of signal transduction such

as G-protein phosphorylation, cAMP or phosphatidylinositol turnover, and adenylate cyclase or phospholipase C activation.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for ligand binding. Other candidate compounds include mutant receptors or appropriate fragments containing mutations that affect receptor function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) receptor activity. The assays typically involve an assay of events in the signal transduction pathway that indicate receptor activity. Thus, a cellular process such as proliferation, the expression of genes that are up- or down-regulated in response to the receptor protein dependent signal cascade, can be assayed. In one embodiment, the regulatory region of such genes can be operably linked to a marker that is easily detectable, such as luciferase.

Any of the biological or biochemical functions mediated by the receptor can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the receptor can be assayed (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

Binding and/or activating compounds can also be screened by using chimeric receptor proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a G-protein-binding region can be used that

interacts with a different G-protein than that which is recognized by the native receptor. Accordingly, a different set of signal transduction components is available as an end-point assay for activation.

Alternatively, the entire transmembrane portion or subregions (such as transmembrane segments or intracellular or extracellular loops) can be replaced with the entire transmembrane portion or

5 subregions specific to a host cell that is different from the host cell from which the amino terminal extracellular domain and/or the G-protein-binding region are derived. This allows for assays to be performed in other than the specific host cell from which the receptor is derived. Alternatively, the amino terminal extracellular domain (and/or other ligand-binding regions) could be replaced by a domain (and/or other binding region) binding a different ligand, thus, providing an assay for test
10 compounds that interact with the heterologous amino terminal extracellular domain (or region) but still cause signal transduction. Finally, activation can be detected by a reporter gene containing an easily detectable coding region operably linked to a transcriptional regulatory sequence that is part of the native signal transduction pathway.

The receptor polypeptides are also useful in competition binding assays in methods designed to
15 discover compounds that interact with the receptor. Thus, a compound is exposed to a receptor polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble receptor polypeptide is also added to the mixture. If the test compound interacts with the soluble receptor polypeptide, it decreases the amount of complex formed or activity from the receptor target. This type of assay is particularly useful in cases in which compounds are sought that
20 interact with specific regions of the receptor. Thus, the soluble polypeptide that competes with the target receptor region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the receptor protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

25 Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound,
30 and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of receptor-binding protein found in the bead fraction quantitated from

the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein
5 trapped in the wells by antibody conjugation. Preparations of a receptor-binding protein and a candidate compound are incubated in the receptor protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using
10 antibodies reactive with the receptor protein target molecule, or which are reactive with receptor protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the GPCRs of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems
15 are well known in the art and can readily be employed in this context.

Modulators of receptor protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the receptor pathway, by treating cells or tissues that express the GPCR (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). These methods of treatment include the
20 steps of administering a modulator of the GPCR's activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the GPCR proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993)
25 *Biotechniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the GPCR and are involved in GPCR activity. Such GPCR-binding proteins are also likely to be involved in the propagation of signals by the GPCR proteins or GPCR targets as, for example, downstream elements of a GPCR-mediated signaling pathway. Alternatively, such GPCR-binding proteins are likely to be GPCR
30 inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a GPCR protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other

construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a GPCR-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the GPCR protein.

10 This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a GPCR modulating agent, an antisense GPCR nucleic acid molecule, a GPCR-specific antibody, or a GPCR-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or insect model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

20 The GPCR proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). The method involves contacting a biological sample with a compound capable of interacting with the receptor protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

25 One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

30 The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion,

insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered receptor activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques
5 useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagents, such as an antibody or protein binding agent.. Alternatively, the peptide can be detected *in vivo* in a
10 subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

15 The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11) :983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic
20 failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or
25 therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the
30 receptor protein in which one or more of the receptor functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding regions that are more or less active in ligand binding, and receptor activation. Accordingly, ligand dosage would necessarily be modified to

maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Accordingly, methods for treatment include the use of the GPCR protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods.

Antibodies are preferably prepared from regions or discrete fragments of the GPCR proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or receptor/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function, particularly in cells and tissues that express the receptor (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of

expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells
5 in the various tissues in an organism (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or
10 relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical
15 assays known to those in the art.

The antibodies are also useful for tissue typing (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding
20 of the GPCR peptide to a binding partner such as a ligand. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against
25 intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of
30 protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a GPCR peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the GPCR peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figures 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ

ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule, for example from about 1-300 additional nucleotides.

The present invention further provides nucleic acid molecules that are comprised of the
5 nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule is comprised of a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid
10 residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the
15 source of the present invention, human genomic sequences (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding
20 regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or
25 carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular
30 enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the GPCR peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional

non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the GPCR proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene (The GPCR of the present invention is encoded by a gene on chromosome 13 near markers SHGC-68276 (LOD=8.71) and SHGC-8118 (LOD=7.82)).

Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2 (Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.).

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

5 The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

 The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into
10 the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

 The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

 The nucleic acid molecules are also useful as probes for determining the chromosomal
15 positions of the nucleic acid molecules by means of *in situ* hybridization methods (The GPCR of the present invention is encoded by a gene on chromosome 13 near markers SHGC-68276 (LOD=8.71) and SHGC-8118 (LOD=7.82).). This is particularly useful in determining whether a particular protein is an allelic variant of one the proteins provided herein

 The nucleic acid molecules are also useful in making vectors containing the gene regulatory
20 regions of the nucleic acid molecules of the present invention as described in detail below.

 The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

 The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

25 The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

 The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

 The nucleic acid molecules are also useful as hybridization probes for determining the
30 presence, level, form and distribution of nucleic acid expression. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to

assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in GPCR protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a GPCR protein, such as by measuring a level of a receptor-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a receptor gene has been mutated (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate GPCR nucleic acid expression, particularly in cells and tissues that express the receptor (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.).

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the GPCR gene. The method typically includes assaying the ability of the compound to modulate the expression of the GPCR nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired GPCR nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the GPCR nucleic acid (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.) or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for GPCR nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the GPCR protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of GPCR gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of GPCR mRNA in the presence of the candidate compound is compared to the level of expression of GPCR mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of

mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

5 The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate GPCR nucleic acid expression, particularly to modulate activities within a cell or tissue that expresses the proteins (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). Modulation includes both up-regulation (i.e. activation or agonization) or
10 down-regulation (suppression or antagonization) or nucleic acid expression.

 Alternatively, a modulator for GPCR nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the GPCR nucleic acid expression in the cells and tissues that express the protein (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA
15 panel screening.).

 The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the GPCR gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance.
20 The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

25 The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in GPCR nucleic acid, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in GPCR genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally-occurring genetic mutations in the GPCR gene and thereby to determine whether a subject with the mutation is at
30 risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the GPCR gene associated with a dysfunction

provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a GPCR protein.

Individuals carrying mutations in the GPCR gene can be detected at the nucleic acid level by a variety of techniques (The GPCR of the present invention is encoded by a gene on chromosome 13 near markers SHGC-68276 (LOD=8.71) and SHGC-8118 (LOD=7.82).). Genomic DNA can be
5 analyzed directly or can be amplified by using PCR prior to analysis (Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.). RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase
10 chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient,
15 isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the
20 amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a GPCR gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the
25 presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences
30 between a mutant GPCR gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include, selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the GPCR gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control GPCR gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of GPCR protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into GPCR protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of GPCR nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired GPCR nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the GPCR protein, such as ligand binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in GPCR gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired GPCR protein to treat the individual.

5 The invention also encompasses kits for detecting the presence of a GPCR nucleic acid in a biological sample, particularly cells and tissues that normally express the protein (The GPCR of the present invention is expressed in the brain, uterus, placenta and fetal brain as determined by cDNA panel screening.). For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting GPCR nucleic acid in a biological sample; means for determining
10 the amount of GPCR nucleic acid in the sample; and means for comparing the amount of GPCR nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect GPCR protein mRNA or DNA.

15 Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or
20 oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee et al., PCT application W095/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in
25 their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et. al., US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in
30 length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length

of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be

obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the GPCR proteins/peptides of the present invention and allelic variation within this gene/protein. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes or alleles, at least one of which is a gene and or alleles of the GPCR gene of the present invention (Figure 3 provides SNP information that has been found in the gene encoding the GPCR proteins of the present invention. The following variations were seen: A6613T, A7338G and A7732C.).

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the GPCR disclosed herein; and (b) one or

more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified GPCR genes of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in procaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the

nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

5 The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

10 In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

15 In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*.
20 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

 A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40,
25 Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, eg. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

30 The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in a host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured

insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian
5 expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for
10 maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein
15 are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression,
20 tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein
25 into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

30 Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one

vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be
5 replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers
10 include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell- free transcription and translation
15 systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as GPCRs, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to
20 these peptides.

Where the peptide is not secreted into the medium, which is typically the case with GPCRs, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid
25 extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the
30 cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a GPCR protein or peptide that can be further purified to produce desired amounts of GPCR protein or fragments. Thus, host cells containing expression
5 vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the GPCR protein or GPCR protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native GPCR protein is useful for assaying compounds that stimulate or inhibit GPCR protein function.

10 Host cells are also useful for identifying GPCR protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant GPCR protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native GPCR protein.

15 Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic
20 animal. These animals are useful for studying the function of a GPCR protein and identifying and evaluating modulators of GPCR protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a
25 pseudopregnant female foster animal. Any of the GPCR protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct
30 expression of the GPCR protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory

Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic
5 animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the
10 *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al. PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al. Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein is required. Such animals can be
15 provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al. Nature* 385:810-813 (1997) and PCT International
20 Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant
25 female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect ligand binding, GPCR protein
30 activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* GPCR protein function, including ligand interaction, the effect of specific mutant GPCR proteins on GPCR protein function and ligand interaction, and the effect of chimeric GPCR proteins. It is also possible to assess

the effect of null mutations, that is mutations that substantially or completely eliminate one or more GPCR protein functions.

5 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred
10 embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic); and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic); and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic);
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.
16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.

17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human proteases, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human protease peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human protease peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic).

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 (transcript) or 3 (genomic).

1/7

```

1  ATGAATGAGC CACTAGACTA TTTAGCAAAT GCTTCTGATT TCCCCGATTA
51  TGCAGCTGCT TTTGGAAATT GCACTGATGA AAACATCCCA CTCAGATGTC
101 ACTACCTCCC TGTATTATAT GGCATTATCT TCCTCGTGGG ATTCCAGGC
151 AATGCAGTAG TGATATCCAC TTACATTTTC AAAATGAGAC CTTGGAAGAG
201 CAGCACCATC ATTATGCTGA ACCTGGCCTG CACAGATCTG CTGTATCTGA
251 CCAGCCTCCC CTTCTGATT CACTACTATG CCAGTGGCGA AAACGGATC
301 TTTGGAGATT TCATGTGTAA GTTTATCOGC TTCAGCTTCC ATTTCAACCT
351 GTATAGCAGC ATCCTCTTCC TCACCTGTTT CAGCATCTTC CGCTACTGTG
401 TGATCATTTCA CCCAATGAGC TGCTTTTCCA TTCACAAAAC TCGATGTGCA
451 GTTGTAGCCT GTGCTGTGGT GTGGATCATT TCACTGGTAG CTGTCATTCC
501 GATGACCTTC TTGATCACAT CAACCAACAG GACCAACAGA TCAGCCTGTC
551 TCGACCTCAC CAGTTCGGAT GAACTCAATA CTATTAAGTG GTACAACCTG
601 ATTTTGAAGT CAACTACTTT CTGCCTCCCC TTGGTGATAG TGACACTTTG
651 CTATACCACG ATTATCCACA CTCTGACCCA TGGACTGCAA ACTGACAGCT
701 GCCTTAAGCA GAAAGCACGA AGGCTAACCA TTCTGCTACT CCTTGCATTT
751 TAGTATGTTT TTTTACCCTT CCATATCTTG AGGGTCATTC GGATCGAATC
801 TCGCCTGCTT TCAATCAGTT GTTCCATTGA GAATCAGATC CATGAAGCTT
851 ACATCGTTTC TAGACCATTA GCTGCTCTGA ACACCTTTGG TAACCTGTTA
901 CTATATGTGG TGGTCAGCGA CAACTTTCAG CAGGCTGTCT GCTCAACAGT
951 GAGATGCAAA GTAAGCGGGA ACCTTGAGCA AGCAAAGAAA ATTAGTTACT
1001 CAAACAACCC TTGA

```

FEATURES:

Start: 1

Stop: 1012

HOMOLOGOUS PROTEIN:

gi 6679193 ref NP_032798.1 purinergic receptor P2Y, G-protein ...	226	2e-58
gi 4505557 ref NP_002554.1 purinergic receptor P2Y, G-protein ...	223	2e-57
gi 1352695 sp P49651 P2YR_RAT P2Y PURINOCEPTOR 1 (ATP RECEPTOR)...	222	3e-57
gi 464327 sp P34996 P2YR_CHICK P2Y PURINOCEPTOR 1 (ATP RECEPTOR)...	221	7e-57
gi 1352693 sp P49652 P2YR_MELGA P2Y PURINOCEPTOR 1 (ATP RECEPTO...	221	7e-57
gi 1352691 sp P48042 P2YR_BOVIN P2Y PURINOCEPTOR 1 (ATP RECEPTO...	221	7e-57
gi 1082756 pir S54253 purinergic receptor - human >gi 798836 e...	217	1e-55
gi 2829680 sp P79928 P2Y8_XENLA P2Y PURINOCEPTOR 8 (P2Y8) >gi 1...	217	2e-55
gi 2707256 gb AAC60339.1 (AF031897) G protein coupled P2Y nucl...	215	7e-55

blast to dbEST:

gi 7921097 gb AW827323.1 AW827323 hm31f01.x1 NCI_CGAP_Thy4 Homo...	46	0.022
gi 2900654 gb AA826657.1 AA826657 of34e08.s1 NCI_CGAP_Kid6 Homo...	42	0.35

Expression information for modulatory use (from cDNA panel screening):

Human uterus
 Human Placenta
 Human Brain
 Human Fetal Brain

FIGURE 1

2/7

```

      1 MNEPLDYLAN ASDFPDYAAA FGNCTDENIP LKMHYLPVIY GIIFLVGFPG
     51 NAVVISTYIF KMRPWKSSTI IMLNLACTDL LYLTSLPFLI HYYASGENWI
    101 FGDfMCKFIR FSfHfNLYSS ILfLTfCfSfSf RYCVIIHPMS CFSIHKTRCA
    151 VVACAVVWII SLVAVIPMTF LITSTNRTNR SACLDLTSSD ELNTIKWYNL
    201 ILTATTFCLP LVIVTLCYTT IIHTLTHGLQ TDSCCLKQKAR RTILLLLAF
    251 YVCFLPFHIL RVIRIESRLI SISCSfENQI HEAYIVSRPL AALNTFGNLL
    301 LYVVVSDNFQ QAVCSTVRCK VSGNLEQAKK ISYSNNP

```

FEATURES:**Functional domains and key regions:**

[1] PDOC00001 PS00001 ASN_GLYCOSYLATIONN-glycosylation site

Number of matches: 4

```

      1      10-13 NASD
      2      23-26 NCTD
      3     176-179 NRTN
      4     179-182 NRSA

```

-----[2]
 PDOC00004 PS00004 CAMP_PHOSPHO_SITEcAMP- and cGMP-dependent protein kinase
 phosphorylation site

Number of matches: 2

```

      1     240-243 RRLT
      2     329-332 KKIS

```

-----[3]
 PDOC00005 PS00005 PKC_PHOSPHO_SITEProtein kinase C phosphorylation site

Number of matches: 4

```

      1     175-177 TNR
      2     178-180 TNR
      3     175-177 TNR
      4     178-180 TNR

```

-----[4]
 PDOC00006 PS00006 CK2_PHOSPHO_SITECasein kinase II phosphorylation site

Number of matches: 2

```

      1     187-190 TSSD
      2     188-191 SSDE

```

Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	33	53	1.690	Certain
2	75	95	0.979	Putative
3	111	131	1.423	Certain
4	154	174	2.274	Certain
5	200	220	2.019	Certain
6	241	261	1.875	Certain
7	288	308	0.757	Putative

3/7

BLAST Alignment to Top Hit:

```

>gi|6679193|ref|NP_032798.1| purinergic receptor P2Y, G-protein
coupled 1 >gi|1352694|sp|P49650|P2YR_MOUSE P2Y
PURINOCEPTOR 1 (ATP RECEPTOR) (P2Y1) (PURINERGIC
RECEPTOR) >gi|767871|gb|AAA91302.1| (U22829) P2Y
purinoceptor [Mus musculus] >gi|6013075|emb|CAB57317.1|
(AJ245636) P2Y1 receptor [Mus musculus]
Length = 373

Score = 226 bits (571), Expect = 2e-58
Identities = 109/299 (36%), Positives = 176/299 (58%), Gaps = 4/299 (1%)

Query: 24  CTDENIPLKMHYLPVIYGIIFLVGPGNAVVISTYIFKMRPWKSSTIIMLNACTDLLYL 83
          C      + YLP +Y ++F++GF GN+V I  ++F M+PW  ++ M NLA  D LY+
Sbjct: 42  CALTKTGFQFYFLPAVYILVFIIGFLGNSVAIWMFVFHMKPWSGISVYMFNLALADFLYV 101

Query: 84  TSLPFLIHYASGENWIFGDFMCKFIRFSFHFNLVSSILFLTCSIFRYCVIIHPMSCFS 143
          +LP LI YY +  +WIFGD MCK RF FH NLY SILELTC S  RY  +++P+
Sbjct: 102 LTLPALIFYFYFNKTDWIFGDAMCKLQRFIFHVNLYGSILFLTCISAHRYSGVVYPLKSLG 161

Query: 144 IHKTRCAVVACAVVWIIISLVAVIPMTFLITSTNRTNRS-ACLDLTSSDELNTIKWYNLIL 202
          K + A+  +VW+I +VA+ P+ F  + R N++ C D TS+D L +  Y++
Sbjct: 162 RLKKKNAIYVSVLVVLIVVVAISPILFYSGTGTRKNKTVTCYDTSNDYLSYFIYSMCT 221

Query: 203 TATTFCLPLVIVITLCYTTIHTLTHGLQTDSCCLKQKARRLTILLLLAFYVCFLPFHILRV 262
          T  FC+PLV++ CY I+ L +  +S L++K+ L I++L F V ++PFH+++
Sbjct: 222 TVAMFCIPLVLILGCYGLIVKALTYNDLNSPLRRKSIYLVIIIVLTVFAVSYPFHVMKT 281

Query: 263 IRIESRL---LSISCSIENQIHEAYIVSRPLAALNTFGNLLLYVVVSDNFQQAVCSTVR 318
          + + +RL      C  ++++ Y V+R LA+LN+  + +LY +  D F++ +  R
Sbjct: 282 MNLRLARLDFQTPEMCDFNDRVYATYQVTRGLASLNSCVDPILYFLAGDTFRRLSRATR 340

```

Hmmer search results (Pfam):

Scores for sequence family classification (score includes all domains):

N	Model	Description	Score	E-value
1	CE00175	CE00175 Purinoceptors	247.2	2.2e-70
1	PF00001	7 transmembrane receptor (rhodopsin family)	168.6	2.1e-52
1	CE00340	E00340 thrombin receptor	101.2	1.4e-27
1	CE00530	CE00530 CHEMOKINE_RECEPTOR_TYPE_4	84.5	3.9e-26
2	CE00521	CE00521 THROMBIN_RECEPTOR	80.2	4.3e-28
2	CE00501	CE00501 ANGIOTENSIN_RECEPTOR	74.1	2e-19
2	CE00529	CE00529 CHEMOKINE_RECEPTOR_TYPE_3	62.2	1.4e-18
2	CE00505	CE00505 CHEMOKINE_RECEPTOR	54.9	1.3e-14
1	CE00319	E00319 adrenomedullin receptor	49.7	1.6e-14
1	CE00531	CE00531 CHEMOKINE_RECEPTOR_TYPE_5	48.8	5.2e-13
1	CE00519	CE00519 BRADYKININ_RECEPTOR	48.8	2.2e-12
1	CE00207	CE00207 PURINERGIC	47.9	7.2e-14
1	CE00179	CE00179 Burkitts_lymphoma_receptor	39.1	5.6e-10

4/7

```

1  GTCCAGTGTG CTCGAAAGTG TCAGAATTTT CTTTCAATTTT AAAACTGAAT
51  AATGTTCCAT GGAATGTATA CATCACATTT TCTTCATCCA TTGATAGGCA
101 CTTGGGCTGC ATCCACATTT TGGCTATTGT GAATAATGCT GCTATGAACA
151 TGGGTGTGCA AGTATCCGTT TGAGTCTCAG CTTTCAATTC TTTGGGGTAT
201 ATTCCCAGAA GCAGAATTGC TGGCTTGTGT CATAATTCTA TTTTAAATTT
251 TTAGAGGAAC CATTATACTT TTTTTTTTC ATAGCACCTG CACAATTTTA
301 ACTTTACAGG ACTGGATATT TTTAAATGTC CTTTCCATGT CTAGAGTTCT
351 AGGACCCAGT ACTTGTTTTT CAAATAACCT CTTTAAGTCA TTTCCTCGTT
401 AGCTGGAAAT CCTGCTCACC ATGGA AAAAC ACTGGGATGT CTTTACTTTC
451 AGAAAGCCTT CATTTGGGTT TAGTCCCTC CCAGCCCTT ATTTACAAGT
501 TGGAGAGGCT AATCATGTTT TTAATTTATT TCTTGTTTTC CTATAAGACA
551 TCAGCTCCTG GAAGCAAAGA TTATGTATTA TTCTTCAATA TCTCCACGGT
601 GCTTGACACA GAATAATCAA ACAGCAAATG TCTGATCAAT GCATAGGTGG
651 GAACAAACAA GGGTCAACTA TTTCCAGATG AAGAATTGAA AAAATGATTA
701 AACATAGTAA AATTAGAGAA CATTTTTCCT CCTAATGCAA AATATTTTCC
751 TGGAGAGGCT GGAATTCAAA TAATCAAAAT GATAAGCATG ATAATAAAAA
801 TGCCTAACTA GGGCTATCCC AACCATCAGC CAGGGCGGAA TCTTCCACC
851 TGGGCCCTGG TGGACACCT AACCTAACAT TCTTGCTCCT GCTGGCTGGC
901 ATTCCCAGAG GATGGGCTAT ACATGGTGTG TGATGCCCAT CAACATGGAA
951 TGTGGAAGA GACATTCAT GCCGTCAT GGAAGAGCGA AGAGGGGCAT
1001 TCTCCAAGCA CCCCCATTCT CTAATACAGT GAACTCTTTG ATGCTGGAAG
1051 AGATCTTGAA GTTCAACGGT TCGGGAGGCG CTAGTATACT GGACGATGTG
1101 GCTGAGGTTC AGAGAAGAGA AAAGGCGATT CCTAAGTTAT GTAGCAAGAA
1151 GGCAACCTAC TCCTAGATC TGGAGATACA GACAAACGCT CTTTGCAGGG
1201 ATAGAAACTA TTTTAAAGCC ACCTTGCTAA GCGCTGGAGG GCAGGGTTGT
1251 AATTGGATAC AGGGAATGA CAACGCTTCA GTAAGTCGCC TCCATCCCAC
1301 GCTAAATAAG AGGCACTGGA CGCTGGGCG ACAGAGCGAG ACTCCTTCTC
1351 AAAAGAAAAA AAAAAAAG AGGCACTGGG CTGTAGGAGA GTGGTGAAT
1401 TTTGTGACCA AGACAAGGCG GCCACAACCC TCCTGGGGCA ACAACCTCC
1451 CGCCGGGCTG GTTTTTGGA ACCTCTGCAA ACACTTTCTC CTGGGTCACT
1501 TTCCCGCCAA ACCGGGATGG AGGATGTCCA GAGTCCCGG GAGTGGAAAGC
1551 CGCTGTCCCT GTGTCTACTG GGAAGTGGGC GAGGCGGGAT GCTGCTGGCC
1601 AGGCTGCTCG GGGCAGGAC CCGAGAACAC GCACTTGCTC CTGGGCCTC
1651 GAGGGGGTGG GAGGGGCGGG GCGGTGCGCA GCCTCCCCGG GACAGGTCTG
1701 CGGTCCGGGA CCAACTAGGC TGCACAGGCA CGCGGGGCGC ATGTCCGCCT
1751 CGCCGGGGCT GCCAGGTGAG CCGCGCGTGA TCGGGGAGCG GGGCCACCG
1801 GCCGGAGGGA GCGGGTATAG GGGACCCTGC CCTGACCCGG AGGGAGACGG
1851 GCGGTGCCCG AGGAGCAGGG GAAAGAGCAC CCCCAGCATG CCCTGCAGCA
1901 GGCAGGGTCG GACGGAGCAG CGCCCCCTTC TTCTCTGGAG GCAGCAGGAG
1951 CACCCAGAT CCTGTGGCGG GAGGCGAAGT TTCATTTTAG GGAACAAAAA
2001 CCCAGGGCG AGAAGACATT TGAATGGAG AGAAGTGGG GAGTTAGGGA
2051 TCGTGATTT CATCTCACAC TTTTTCAC ACCCAAGCGA GGGGTCTGGG
2101 AGGTGGGCAG GGAGAGTGTCT TAGGAGACAA ACAGAGTTAA TCCCTCAGCC
2151 CATTGATCAC CGCCCTGCTG AATGTTCTCA AAGCTCAGCC TGCATCGTGG
2201 TGGACTGTGT GGTGTTGGAA ACGACCAAAG ACTCTGCCCC ACCCCACCC
2251 CCAACAAGCG AGGAAAATGT TTCCCTGAA ATGTCTTTCT TCTCTGTCTT
2301 TCTTTTGTG TCGTTGCTAT GGATTCGTGA ACTAGCTTGT AATGGTCTAT
2351 AAACCTCTAA CTTGTATGTA TAATATTTGC GTGTCCATGC ATGCATTTT
2401 CTGAAGCGAG CTCTCAGAAG TTGTATTTGT TTCTCCCGAA GAATAAATAG
2451 GCAAAACCAT ATCTTTGGGC TGCATCAACA TGACCTCTTA ATAGTCTTCA
2501 GGGAAACTGA GTTGCAGATT CTTATTTAAC GAATGGGGA TTGGCCGGGT
2551 GTGTGGCTCA CGTCTGTAAT CCCAGCACTT TGGGAGGCTG AGGCAGGTGG
2601 ATCACCTGAG GTCAGTAGTT CGAGACCAGC CTGGCCAACA GGCTGGTGAA
2651 ACCCTGTCTC TATACAAATA CAAAAATTA GCCAGACGTG GTGGAACGGG
2701 CCTGTAATCC CAGCCACTCC GAGGCTGAGG CAGGAGGATC CCTGAACCC
2751 AGCAGGTGGA GGTGAAGTG CGCCAAGATC ATGGCCACTG CACTCCAGTC
2801 TGGGCGACAG AGCAAGATTT CGTCTCCAAA ACAACAACAA CAATAATAAC
2851 ACAAAACAAC AAAAAACAAT AAAGTGGGGA TTGAGGGAAG AGCCTTGAGG
2901 CTCCCAGAA GGTGGGGGAG AAAGATTCCCT TCAGGGACCA GGGAGGACAG
2951 CACTTACCA GTCAAAATT TACCTGTTT AAGAATTGGT CTCTTTTCCA
3001 CCAGTATGAA GTACAATTAG TTTTCAAATA TGTAGACTGG GAAATCGAAG
3051 TAAGTCTTTG TGAATGAAAG GTCTACTTAA GTTCTTTTT GACAACCCAA
3101 AGTGACCCCA GCTTCGGAGC TTCCAAGGAC TCTGGAGAGA AGGTAACAGA
3151 TTAAGTGTTC CAACTGTGCA CCTCCCTCGT CCATTGGCAT CTTGGGAAAA
3201 GGAGGAAAGA ACCAACTGTG ACCTCAGCAT GGGAGCAGAA CCAGAAAAAC
3251 CCAGGGAGTC TGGGGGAGAG GGAGGAGAGC AGGGAGAGGT ACAGGCATTG
3301 TTGGATAATG AGCTTAACCT ATCCAACAAA GCTGATCTGC AAAACCAACA
3351 GGCACCTTAG GAAATCACA TTTCATCAT AATCCCACTT TCTTGTTC

```

FIGURE 3, sheet 1 of 4

5/7

```

3401 CAAATGGGCA AGAGTACTCT GTGGAGGTGA AGTAGTATCT GCTGCCACTT
3451 AACTGGATAG CATTTCTGAT CCTGCCTTCT TTACCCACAG AATCTTGGAA
3501 TCCCAATCCG TGAGGTTCCT GGGTGTGCTG GCATCAGGAC AGCGGTCCAC
3551 GAACGGTGTG TTACCCAAAT ATTGACATCC TGCAGCTGGC CTCAAACAAT
3601 CACAGCTACT TTCCAATTTT AGAGAAAAAA AGGCTAAAAA TGTAAGCTTT
3651 TTCTTAACAA TTTTTTTTAT TCTTAATTTT TGTGGATACA TAGCAGGTAT
3701 ATATAATTAT GGGGTACATG AGATATTTTG ATACAGGCAT GCAATGTGAA
3751 ATAAGCACAT CATAGAGAAT GGGGTATCCA TCCACTCGAG CATGCATCCT
3801 TTGTGTTATT AATACAAACA ATCCACTTAC CTTCTTTATT TAAAAATGTG
3851 CAATTAAGTT ATTATGACTA TGGTCACCCC ATTGTGCCAT CAAATAGTAG
3901 GTCTTAITCA TTCTTTCTAC CTTTCTTTT TTTTGTGTAC ACATTAGCCA
3951 TCCCCTCCAC CAGTCCCCCA CTACTCTTCC CAGCTTCTGG TAACCATCCT
4001 TCTACTCTCT ATGCCCATGA GTTCAGTTGT TTTGATTTT AGATCCCATG
4051 AATGAGTGAG AACATGCAAT GTTTGTCTTT CCATGCCTGG CTTTTTTCAC
4101 TTCCCATAAAT GACCTCCAGT TCTACCCATG AGGTTGCAAA TGACAGGATC
4151 TCATTCTTTT TTATGGCTGA ATAGTACTCC ACCATGTATA AGTACCACAT
4201 TTTCTTTATC CATTCATCTG TGGATGGACA CTTAGGTTGC TTCCAAATCT
4251 TGGCTACTGT GAACAGGGCT GCAACAAACA TGGGAATGCG GATAGCTCTT
4301 TGATATACTG ATTTCCCTTC TTTTGGGTAT ATACTCAGCA GTGGAAATGC
4351 TGGATCATAT GGTAGCTCAG TTTTAGTTT GCTGAGGAAC CTCCAAACTG
4401 TTCTCCATAG TGATTGTACT AAAATTATAA GCTTTTCTT CACAAGTTTA
4451 TTCCAACCTT TGATGCTGGC TTTTATTCAT GCTGAACCTA GCTTAGTTCA
4501 CACTTATATT TTTGGTTATG TTAAAGCTGA ATACATCATT ATTTCTTGCT
4551 TGCAAAGAAC CCATTGGTTT CAAGTGATTT GTAACCTCCT CACGTTTGAG
4601 AACTACTGTT GTAGAAAGAG AAGGGAATAT ACCCAGGGT GTGCCACATT
4651 TGTCTTTAAT GTCCTTTGAG TTGAAATGAT TTGTTGTGG ACCATCTGGT
4701 GTTCTGAGTT GTGGCAGTGA ATTGCACTGG GCCCTGAAGC TAGGGAGGAA
4751 AGAAACAGCT TCATCCTACC TGCTCACAGC CCAGACCGGT TTTTGTGTG
4801 CTGTTGTTAA CATCACACGT ATTTTGTAAG CTCATACTT TATGAGGTTT
4851 TATGGAACAC AGATTAAGCT TCCTAGTCAA CCCCTCCACC CTTACAATTG
4901 GCTAGTCAGT CTTCAATCAA TCTGAATTGA ACTATTGTTT TTCAGAACAA
4951 TAAGGCAGTT GTTCTACCT ATAACCCATC TTTTCTTCAT AGAATTATTG
5001 TTTAACATGG TCTCCATAAC ATGGCTAAGG GTTTATTTGG CAATGACAGG
5051 AATTGTAATT TTGCTTCCTA CTTTAAAGT CATGAAAGAT CTAAGCTTGC
5101 TTTTTTTTTT TTTTTTTTTT TGAAAGAGTC TTGCTGTGTC ACTCAGGCTG
5151 TAGTACAGTG GCTCAATCTC GGCTTACTGC AGCCTACACC TCCCAGGTTT
5201 AAGCGATTCT CGTGCCTCAG CCTCCCAAGT AGCTGGGACT ATAGGCATGG
5251 GCCACCACAC CCAGCTACGT TTTTTTTTGT ATTTTAAATA GAGACGGAGT
5301 TTTGCAATGC TGGCCAGGCA GGCTCGAAC TCCTGACCTT GGGCGATCCG
5351 CCTGCCTCAG CCTCCCAAAG TGCTGAGGTT ACAGGCTTGA GCCACTGTGC
5401 CTGGCCTAAG AACCAAGCTT TTTTITAGAA TGATAGTTGC CCCTTCAGTA
5451 GCCCTTCAGT ACCATATAAG TTTTGTGAT GTTACTGGTT GTTCTTTAAT
5501 GCATTACAGCA AATATTAATA TTTACTGCAC ACCTTCCATG TGCCAGCCCC
5551 TGGGGTATGA GGTGACTTGT GTTTTCTTT CAAGGAGCTG ACAAATAAGC
5601 AGCTTGGACT TGAATTCCTT CCCCTTCTCT TCCTCTCAGT TCTCTGTTGA
5651 GGCAAATCCC AATTGGAATG AAATAACTCT GGAGAATTAT TTTGGGCGTT
5701 ACTAAAACCTA TCTTTACTTC TTTGCTCCAG AAGCAACATT AGCTACTTAG
5751 TGGCCTCTTG ACATAATCTA AGAACTGTCT TTGGGACGTG CTGCTTCTGG
5801 GACTCCTTGG CTGTGACCAT TTTCTTTCAT GTTTAAGTGA CTTCTGTCTC
5851 CTTATGCATG AGTCCATTTA AGACATTCTG CCAAGGGAGA AGCCATCCAC
5901 TGTGGTTGCC TGGCTTCAGA GCACTCTCAC TGGTCAGCAG TCCCTGACTC
5951 CTATGACCTC CAGTGCTGTG TAGATGATAG TTTTATGAAT AGCACTTTTA
6001 ACATCTATGT TGCATTAGGT ATTATAAGTA ATCTAGAGAT GATTTACAGG
6051 AGGATGGGCA TAGGTTAAGT GTAAATACCA TACCATTTTA TTTTATATC
6101 AGTGACGTGA GCATCTGCAG ATTTTGGTAT CCTTGGGGGT CTGGGAACCA
6151 ATGCACTGCA GATACTAAGG GACAACCTA CAGTGTTTGA TTTATTGAGC
6201 TTTCTGAGAT ATTCAGCCTT TTCCTGTCTT CACACTTGTT TTTCCCTCTA
6251 TTATTTAGGG TAATCCTGAT GAAAATCAAC AAAATACACA TGAAGAGACA
6301 GCACTGAGAG GTAATGTGCT AACTGGTCTT TGTGATTACA GGCACCTCAG
6351 ATTTCCCTCT TGCCTACTCA TTGTGAGATG CAGCCCAGCC CTGCAACAAG
6401 ACTGCCACAG TCGTATCCTG GCTCACCCTT AACTAGCGGT TTGACTTTGA
6451 GCACATCACT GCCTCCTCCG TGCCTCAGT TCCTCTTCTG TTGAATGGGG
6501 ATGATCACAG CACTACCTCA CCATTGTGTG TGAGGATTAA ATAGATTCAA
6551 ATATGTAAGA CACTTACAGT AATGCTTTGT ACACAGAAGG CACTATTATT
6601 TTTTATTAAT CCTATTTTTT CCTCCCAAC TTCATCTCCC AATATCCCAT
6651 AACCATGCTG ATTTCCCTTAC AACTCCCCCA GACCTCCTGG ACTAAGTGAG
6701 ATTTGGAAGA GTATACTCAG GGCAGTCAAG AAGGACTGAT TCTGCTAATT
6751 TAGGATTTGT CAAGTTGGGT TAGTTTGAAA TATACCTCTG TACTCCTCTC

```

FIGURE 3, sheet 2 of 4

6/7

```

6801 AGGAAATGCT GGATAGTGTA GATTTAGTAT CAGATAATAG TAATAATGGT
6851 GGCAGACTCT GATGTTTCCT CCTTCCCCTG TGATCTCAGT AGTCTTGTA
6901 CATTTCATACA TCRAATGACT TAGCAACTAA CAATCACGTA ATATTTTTTA
6951 AGCTTTTCTT ATGTGCCCAG TAGTGAGCCA AGAGTTTTTT TTCCTATTTT
7001 TAACATACTA TTGACAGCTC CATGAGGTGG GTTTATATTT TGTAAAAATA
7051 ATTTGCCATG TCCACTTCCC CAGTAGACTG TGACAGTGGC ATATACATCT
7101 GTGTGTGTTA TTCAGTTTGT ATCTCTAGGA CTTGACAGAG GACCCAATAC
7151 AGAGTGGGTG CTCCAGAAAT GTGGACTTGG ATGCATTTCA CCAACAGCTA
7201 TTTACATCCA AATAATAAGC TAATTATAAC TCTTCTTCTA GATGTACTTT
7251 TCTCATTGCA AAAATTCACC GTCAAAATTT TAAAAACAC TAATAAGCAA
7301 GAAGAAGGAA GTTAAATTTG CACTCCTTCC AGCCCTAAAG AGCTTAATCA
7351 ACTTGCTTAG GAACACGCTA CTAATATGGCT AATCTGAGCA CCAAAATCTG
7401 GCCATCTGGC TTCAGGGCTC AGCCTCCTAA TGGCCGCATT ATACCATTGA
7451 TCCC GCCCCA TCCACCCCAA CACACACACT CCCCTGCACA AACAAATTAT
7501 GTTAGCTATT AAAAGGAATT GGAAGAGTGG AAATGTGCAA TTAAATCTAC
7551 CACAAATACA ATGTTGCAAT ACGTGCAATC TATATTTTTA AAATTACAG
7601 TATTCAGCAT TTTCTGTCTC TCACACTTGT TCCCTCCGTT ATTTACGGCA
7651 ATCATGACGA AAATCAACAA AATACAGATT GAGAGGCAGC ACTGAGAGGT
7701 AATGTAGAAA GGGAAATGGCT TTTGAGTCAG AAAAATGCCA GTGTGGATCC
7751 CAGCTAAGCC CTTAGATGTG TTACCAGAGA CGAGCCGCAA AACATTTCTC
7801 AGCTTTATGC TCTTGTAAAA TAGAGGTAAT AAGAAACACT TTTTCAATTT
7851 TTGTGACATG TAGAAGTAAG TGATGGTGGC ATGCATCACA CTTGGTTAAT
7901 AGTAGGTCTT GTTGTAAAGT CTCTAATGGC GATACCCTAT GGCTTCTCCA
7951 AATGGTGACC TTGCCAAATT GTTTTCCAAA GCGACATGTG GCTTTTTTCT
8001 CCCAATCCCT CATTTTAACT CTCATGGTAA TTTAACTTTT ATATTTTTAT
8051 TAGATGCATT TAGTAACTTG CCTCATAGTC ATTTTCTTGG AAATTCAATT
8101 TCTTCTCCAC AGGCTCTCTT TTGAGATTAA AGAGAGAGAA GTGGCAAATT
8151 TAGGATGTTA GAATAATTTT CATTTAAAG TAGATCCTTG TTTTATTAC
8201 CCTATCATTA ATGTTTCTCG TTTTCTTTA TCAGCGAGTT ACTGCTCATT
8251 TGATTTCATAT TGCCAAACTG AACTCTCTTG TTTTCTTGCA AGATGAAAGG
8301 AGACAACCAT GAATGAGCCA CTAGACTATT TAGCAAATGC TTCTGATTTC
8351 CCCGATTATG CAGCTGCTTT TGGAAATGTC ACTGATGAAA ACATCCCACT
8401 CAAGATGCAC TACCTCCCTG TTATTTATGG CATTATCTTC CTCGTGGGAT
8451 TTCCAGGCCAA TGCAGTAGTG ATATCCACTT ACATTTTCAA AATGAGACCT
8501 TGGAAGAGCA GCACCATCAT TATGCTGAAC CTGGCCTGCA CAGATCTGCT
8551 GTATCTGACC AGCCTCCCCT TCCTGATTCA CTACTATGCC AGTGCGGAAA
8601 ACTGGATCTT TGGAGATTTC ATGTGTAAGT TTATCCGCTT CAGCTTCCAT
8651 TTCAACCTGT ATAGCAGCAT CCTCTTCTC ACCTGTTTCA GCATCTTCCG
8701 CTACTGTGTG ATCATTACAC CAATGAGCTG CTTTTCATT CACAAAACCTC
8751 GATGTGCAGT TGTAGCCTGT GCTGTGGTGT GGATCATTTC ACTGGTAGCT
8801 GTCATTCCGA TGACCTTCTT GATCACATCA ACCAACAGGA CCAACAGATC
8851 AGCCTGTCTC GACCTCACCA GTTCGGATGA ACTCAACT ATTAAGTGGT
8901 ACAACCTGAT TTTGACTGCA ACTACTTTCT GCCTCCCCTT GGTGATAGTG
8951 ACACTTTGCT ATACCACGAT TATCCACACT CTGACCCATG GACTGCAAAC
9001 TGACAGCTGC CTTAAGCAGA AAGCACGAAG GCTAACCAAT CTGCTACTCC
9051 TTGCATTTTA CGTATGTTTT TTACCCTTCC ATATCTTGAG GGTCAATCGG
9101 ATCGAATCTC GCCTGCTTTC AATCAGTTGT TCCATTGAGA ATCAGATCCA
9151 TGAAGCTTAC ATCGTTTCTA GACCATTAGC TGCTCTGAAC ACCTTTGGTA
9201 ACCTGTTACT ATATGTGGTG GTCAGCGACA ACTTTCAGCA GGCTGTCTGC
9251 TCAACAGTGA GATGCAAAGT AAGCGGGAAC CTTGAGCAAG CAAAGAAAAT
9301 TAGTTACTCA AACAAACCCTT GAAATATTTC ATTACTTAA CCAAAAACAA
9351 ATACTTGCTG ATACTTTACC TAGCATCCTA AGATGTTTCA GATGTCTCCC
9401 TCAATGGAAC TCCTGGTAAA TACTGTGTAT TCAAGTAATC ATGTGCCAAA
9451 GCCAGGGCAG AGCTTCTAGT TCTTTGCAAT CCCTTTATTG AGCTCCTCCA
9501 CTGGGGAGAT ATAAGAAATGG GATGCATGTA TATCAGCAA GTATTTCAGC
9551 ATAGTATTAC AAGCTATTGG AACTCAGAGG CATCTTAGAG AACATCTGTT
9601 CCCACCAACT TACTATATAT ACACGGAAC CAATTTCTTA CCCTTGCCCT
9651 AGATTGCTCA GTAAATTTGT GCCAAGATAG GAGAAAACCA ATCTTTTCAC
9701 TCATCATTTT ATGCTTCTCT GCACTCTGGG CCTATTTGTA TTGAACCAT
9751 AGACAATTCA AACCACTACT TGTATCTTTC TTAATATTTA TTTTTCACAT
9801 CTCAGAGCTC TACAATTTGT TTCCTTCAAG CTTAACTTTG AGATTATAAA
9851 ACTGGGTTTA GCCAGTTCTG TATATTACTT CAAGCCAGTA AGATACCCCT
9901 GAAAT

```

FEATURES:

Start: 8309

Exon: 8309-9322

7/7

Stop: 9320

Map position for allelic variation:

11000292760378	#	SHGCNAME	CHROM#	LOD_SCORE	DIST. (cRs)
	1	SHGC-68276	13	8.71	14
	2	SHGC-8118	13	7.82	15
	3	SHGC-4149	13	7	22

Allelic variation (SNPs):

Position	Allele 1	Allele 2	Context
7,732	a	c	agaggcagcactgagaggtaatgtagaaaggggaatggcttttgagtcaga[a/c]aaa tgcgagtgtggatcccagctaagcccctagatgtgttaccagagacg
7,338	a	g	cactaataagcaagaagaaggaagttaaaattgcactccttccagcccta[a/g]aga gcttaatacaacttgcttaggaacacgctactaaatggctaatactgag
6,613	c	t	cttacagtaatgctttgtacacagaaggcactattatTTTTTattaatcc[c/t]tat tttccttcccaacttcattctcccaatatcccataaccatgctgatt

			Protein			
POSITION	Allele 1	Allele 2		Position		
7,732	a	c	Intron			
7,338	a	g	Intron			
6,613	c	t	Intron			

SEQUENCE LISTING

<110> WEI, Ming-Hui et al

<120> ISOLATED HUMAN G-PROTEIN COUPLED
RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR
PROTEINS, AND USES THEREOF

<130> CL000750-PCT

<140> (tba)

<141> 2001-05-17

<150> US 09/634,656

<151> 2000-08-08

<150> US 60/205,196

<151> 2000-05-18

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1014

<212> DNA

<213> Human

<400> 1

```

atgaatgagc cactagacta tttagcaaat gcttctgatt tccccgatta tgcagctgct 60
tttggaaaatt gcactgatga aaacatocca ctcaagatgc actacctccc tggtatttat 120
ggcattatct tcctcgtggg atttccaggc aatgcagtag tgatatccac ttacattttc 180
aaaatgagac cttggaagag cagcaccatc attatgctga acctggcctg cacagatctg 240
ctgtatctga ccagcctccc ctctctgatt cactactatg ccagtggcga aaactggatc 300
tttggagatt tcatgtgtaa gtttatccgc ttcagcttcc atttcaacct gtatagcagc 360
atcctcttcc tcacctgttt cagcatcttc cgctactgtg tgatcattca cccaatgagc 420
tgcttttcca ttcacaaaac tcgatgtgca gttgtagcct gtgctgtggt gtggatcatt 480
tcactggtag ctgtcattcc gatgaccttc ttgatcacat caaccaacag gaccaacaga 540
tcagcctgtc tcgacctcac cagttcggat gaactcaata ctattaagtg gtacaacctg 600
attttgactg caactacttt ctgcctcccc ttggtgatag tgacactttg ctataccacg 660
attatccaca ctctgaccca tggactgcaa actgacagct gccttaagca gaaagcacga 720
aggctaacca ttctgctact ccttgcatth tacgtatggt ttttaccctt ccatactctg 780
agggtcattc ggatcgaatc tcgctgctt tcaatcagtt gttccattga gaatcagatc 840
catgaagctt acatcgtttc tagaccatta gctgctctga acacctttgg taacctgtta 900
ctatatgtgg tggtcagcga caactttcag caggctgtct gctcaacagt gagatgcaaa 960
gtaagcggga accttgagca agcaaagaaa attagttact caaacaaccc ttga 1014

```

<210> 2

<211> 337

<212> PRT

<213> Human

<400> 2

```

Met Asn Glu Pro Leu Asp Tyr Leu Ala Asn Ala Ser Asp Phe Pro Asp
 1             5             10            15
Tyr Ala Ala Ala Phe Gly Asn Cys Thr Asp Glu Asn Ile Pro Leu Lys
          20          25          30
Met His Tyr Leu Pro Val Ile Tyr Gly Ile Ile Phe Leu Val Gly Phe
      35          40          45
Pro Gly Asn Ala Val Val Ile Ser Thr Tyr Ile Phe Lys Met Arg Pro
 50             55             60

```

Trp Lys Ser Ser Thr Ile Ile Met Leu Asn Leu Ala Cys Thr Asp Leu
 65 70 75 80
 Leu Tyr Leu Thr Ser Leu Pro Phe Leu Ile His Tyr Tyr Ala Ser Gly
 85 90 95
 Glu Asn Trp Ile Phe Gly Asp Phe Met Cys Lys Phe Ile Arg Phe Ser
 100 105 110
 Phe His Phe Asn Leu Tyr Ser Ser Ile Leu Phe Leu Thr Cys Phe Ser
 115 120 125
 Ile Phe Arg Tyr Cys Val Ile Ile His Pro Met Ser Cys Phe Ser Ile
 130 135 140
 His Lys Thr Arg Cys Ala Val Val Ala Cys Ala Val Val Trp Ile Ile
 145 150 155 160
 Ser Leu Val Ala Val Ile Pro Met Thr Phe Leu Ile Thr Ser Thr Asn
 165 170 175
 Arg Thr Asn Arg Ser Ala Cys Leu Asp Leu Thr Ser Ser Asp Glu Leu
 180 185 190
 Asn Thr Ile Lys Trp Tyr Asn Leu Ile Leu Thr Ala Thr Thr Phe Cys
 195 200 205
 Leu Pro Leu Val Ile Val Thr Leu Cys Tyr Thr Thr Ile Ile His Thr
 210 215 220
 Leu Thr His Gly Leu Gln Thr Asp Ser Cys Leu Lys Gln Lys Ala Arg
 225 230 235 240
 Arg Leu Thr Ile Leu Leu Leu Ala Phe Tyr Val Cys Phe Leu Pro
 245 250 255
 Phe His Ile Leu Arg Val Ile Arg Ile Glu Ser Arg Leu Leu Ser Ile
 260 265 270
 Ser Cys Ser Ile Glu Asn Gln Ile His Glu Ala Tyr Ile Val Ser Arg
 275 280 285
 Pro Leu Ala Ala Leu Asn Thr Phe Gly Asn Leu Leu Leu Tyr Val Val
 290 295 300
 Val Ser Asp Asn Phe Gln Gln Ala Val Cys Ser Thr Val Arg Cys Lys
 305 310 315 320
 Val Ser Gly Asn Leu Glu Gln Ala Lys Lys Ile Ser Tyr Ser Asn Asn
 325 330 335
 Pro

<210> 3
 <211> 9905
 <212> DNA
 <213> Human

<400> 3
 gtccagtgtg ctcgaaagtg tcagaatttc cttcattttt aaaactgaat aatgttccat 60
 ggaatgtata catcacattt tcttcattcca ttgataggca cttgggctgc atccacattt 120
 tggctattgt gaataatgct gctatgaaca tgggtgtgca agtatccgtt tgagtctcag 180
 ctttcaattc tttggggtat attcccagaa gcagaattgc tggcttgtgt cataattcta 240
 tttttaattt ttagaggaac cattatactt ttttttttcc atagcacctg cacaatttta 300
 actttacagg actggatatt tttaaatgtc ctttccatgt ctagagttct aggaccaggt 360
 acttggtttt caaataacct ctttaagtca tttcctcgtt agctggaaat cctgctcacc 420
 atggaaaaac actgggatgt cttttacttc agaaagcctt catttgggtt tagtcccctc 480
 ccagcccctt atttacaagt ggcaagccct aatcatgttt ttaatttatt tcttgttttc 540
 ctataagaca tcagctcctg gaagcaaaga ttatgtatta ttcttcaata tctccacggt 600
 gcttgacaca gaataatcaa acagcaaagt tctgatcaat gcatagggtg gaacaaaaca 660
 ggggtcaacta tttccagatg aagaattgaa aaaatgatta aacatagtaa aattagagaa 720
 cattttttct cctaattgcaa aatattttcc tggagaggct ggaattcaaa taatcaaaat 780
 gataagcatg ataataaaaa tgccctaacta gggctatccc aaccatcagc cagggcggaa 840
 tctttccacc tgggcccctg tgggacacct aacctaacat tcttgctcct gctggctggc 900
 attcccagag taggggctat acatgggtgtt tgatgcccac caacatggaa gtgcagaaga 960
 gacattcaat gcccgtccat ggaagagcga agaggggcat tctccaagca cccccattcg 1020
 ctaatacagt gaactctttg atgctggaag agatcttgaa gttcaacggt tcgggaggcg 1080
 ctagtatact ggacgatgtg gctgaggttc agagaagaga aaaggcgatt cctaagttat 1140

gtagcaagaa	ggcaacctac	tccctagatc	tggagataca	gacaaacgct	ctttgcaggg	1200
atagaaacta	tttttaagcc	accttgctaa	gcgctggagg	gcagggttgt	aattggatac	1260
agggaaatga	caacgcttca	gtaagtgcgc	tccatcccac	gctaaataag	aggcactgga	1320
cgcctgggcg	acagagcgag	actccttctc	aaaagaaaaa	aaaaaaaaag	aggcactggg	1380
ctgtaggaga	gtggtgaaat	ttctggacca	agacaaggcg	gccacaaccc	tcctggggca	1440
acaaccctcc	cgccgggctg	gttttttgga	acctctgcaa	acactttctc	ctgggtcagt	1500
ttcccgccaa	accgggatgg	aggatgtcca	gaggtcccgg	gagtggaaag	cgctgtccct	1560
gtgtctactg	ggaagtgggc	gaggcgggat	gctgctggcc	aggctgctcg	gggcgaggac	1620
ccgagaacac	gcacttgctc	gctgggcctc	ggaggggtgg	gaggggcggg	gcggtgcgca	1680
gcctccccgg	gacaggtctg	cggtccggga	ccaactaggc	tgacacaggc	cgcgggcgcg	1740
atgtccgcct	cgccggggct	gccaggtgag	ccgcgcgtga	tcggggagcg	gggcccaccg	1800
gccggaggga	gcgggtatag	gggaccctgc	cctgaccggg	aggagacagg	gaggtgcccg	1860
aggagcaggg	gaaagagcac	ccccgcacgt	ccctgcagca	ggcagggtcg	gacggagcag	1920
cgcccccttc	ttctctggag	gcagcaggag	caccccagat	cctgtggcgg	gaggcgaagt	1980
ttcatttttag	ggaacaaaaa	gcccaggggc	agaagacatt	tgacttggag	agaactgggg	2040
gagttaggga	tcgtgatatt	catctcacac	tttttttcac	acccaagcga	ggggtctggg	2100
aggtgggcag	ggagagtgc	taggagacaa	acagagttaa	tccttcaccc	cattgttcac	2160
cgccctgctg	aatgttctca	aagctcacc	tgcatcgtgg	tggactgtgt	ggtgttggaa	2220
acgaccaaag	actctgcccc	acccccaccc	ccaacaagcg	aggaaaatgt	ttcccctgaa	2280
atgtctttct	tcctgtctct	gttttttgtt	tcgttgctat	ggattcgtga	actagcttgt	2340
aatgggtctat	aaacctctaa	cttgtatgta	taatatttgc	gtgtccatgc	atgcattttt	2400
ctgaagcgag	ctctcagaag	ttgtatttgt	ttctcccgaa	gaataaatag	gcaaaaccat	2460
atctttgggc	tgcatcaaca	tgacctctta	atagtcttca	gggaaactga	gttgcagatt	2520
cttattttaac	gaattgggga	ttggccgggt	gtgtggctca	cgtctgtaat	cccagcattt	2580
tgggaggctg	aggcaggtgg	atcacctgag	gtcagtagtt	cgagaccagc	ctggccaaca	2640
ggctggtgaa	accctgtctc	tatacaata	caaaaaatta	gccagacgtg	gtggaacggg	2700
cctgtaatcc	cagccactcc	gaggctgagg	caggaggatc	ccttgaaccc	aggaggtgga	2760
ggttgaagtg	cgccaagatc	atggccactg	cactccagtc	tgggcgacag	agcaagattt	2820
cgtctccaaa	acaacaacaa	caataataac	acaaacaaac	aaaaaacaa	aaagtgggga	2880
ttgagggag	agccttgagg	ctcccagaag	ggttggggag	aaagattcct	tcagggacca	2940
gggaggacag	cacttaccca	gtcacaaatt	tacctgtttt	aagaattggg	ctcttttcca	3000
ccagtatgaa	gtacaattag	ttttcaata	tgtagactgg	gaaatcgaa	taagtctttg	3060
tgaatgaaag	gtctacttaa	gtttcttttt	gacaacccaa	agtgacccca	gcttcggagc	3120
ttccaaggac	tctggagaga	aggtaacaga	ttaagtgttc	caactgtgca	cctccctcgt	3180
ccattggcat	cttgggaaaa	ggaggaaaga	accaactgtg	acctcagcat	gggagcagaa	3240
ccagaaaaac	ccagggagtc	tgggggagag	ggaggagagc	agggagaggt	acaggcattg	3300
ttggataatg	agcttaactt	atccaacaaa	gctgatctgc	aaaaccaaca	ggcaccttag	3360
gaaaaatcac	tttcatcatt	aatccacttt	ctttgttcc	caaattggga	agagtccttc	3420
gtggagggtga	agtagtatct	gctgccactt	aactggatag	catttctgat	cctgccttct	3480
ttaccacacag	aatcttgga	tcccaatccg	tgaggttcct	gggtgtgctg	gcatcaggac	3540
agcgtgccac	gaacggtgtg	ttacccaa	attgacatcc	tgacagctgc	ctcaaacaat	3600
caagctact	ttccaatttc	agagaaaaaa	aggctaaaat	tgtaagcttt	ttcttaacaa	3660
tttttttatt	tttaattttt	tgtggataca	tagcagggtat	atataattat	ggggtacatg	3720
agatatattg	atacaggcat	gcaatgtgaa	ataagcacat	catagagaat	ggggtattca	3780
tcacactcgag	catgcactcc	ttgtgttatt	aatacaacaa	atccacttac	cttctttatt	3840
taaaaatgtg	caattaaagt	attatgacta	tggtcacccc	attgtgccat	caaatagtag	3900
gtcttattca	ttctttctac	ctttcttttt	ttttttgtac	acattagcca	tcccctccac	3960
cagtccccca	ctactcttcc	cagcttctgg	taaccatcct	tctactctct	atgcccatga	4020
gttcagttgt	tttgattttt	agatcccatg	aatgagtggg	aacatgcaat	gtttgtcttt	4080
ccatgcctgg	cttttttcac	ttcccataat	gacctccagt	tctacctatg	aggttgcaaa	4140
tgacaggatc	tcattctttt	ttatggctga	atagtactcc	accatgtata	agtaccacat	4200
ttcttttatc	cattcatctg	tggatggaca	cttaggttgc	ttccaaatct	tggctactgt	4260
gaacagggct	gcacaacaaa	tgggaatgcg	gatagctctt	tgatatactg	atttcctttc	4320
ttttgggtat	atactcagca	gtggaaatgc	tggatcatat	ggtagctcag	tttttagttt	4380
gctgagggaac	ctccaaactg	ttctccatag	tgattgtact	aaaattataa	gctttttctt	4440
cacaagttta	ttccaacctt	tgatgctggc	ttttattcat	gctgaacctt	gcttagttca	4500
cacttatatt	tttggttatg	ttaaagctga	atacatcatt	atttcttget	tgcaaaagaac	4560
ccattgggtt	caagtgattt	gtaacctcct	cacgtttgag	aactactgtt	gtagaaagag	4620
aagggaatat	accagggtt	gtgccacatt	tgtctttaat	gtcctttgag	ttgaaatgat	4680
ttgtttgtgg	accactgggt	gtgtcaggtg	gtgacagtg	attgcaactg	gccctgaagc	4740
tagggaggaa	agaaacagct	tcactcctacc	tgctcacagc	ccagaccggg	tttttgtgtg	4800
ctgttggtta	catcacacgt	attttgtaaa	ctcatacttt	tatgaggttt	tatggaacac	4860
agattaagct	tcctagtcaa	cccctccacc	cttacaattg	gctagttagt	cttcattcaa	4920

tctgaattga	actattgttt	ttcagaacaa	taaggcagtt	gtttctacct	ataaccatc	4980
ttttcttcat	agaattattg	tttaacatgg	tctccataac	atggctaagg	gtttatttgg	5040
caatgcagag	aattgtaatt	ttgcttccta	ctttaaaagt	catgaaagat	ctaagcttgc	5100
tttttttttt	tttttttttt	tgaaagagtc	ttgctgtgtc	actcaggctg	tagtacagtg	5160
gctcaatctc	ggcttactgc	agcctacacc	tcccagggtc	aagcgattct	cgtgcctcag	5220
cctcccaagt	agctgggact	ataggcatgg	gccaccacac	ccagctacgt	ttttttttgt	5280
atttttaata	gagacggagt	tttgcaatgc	tggccaggca	ggtctcgaac	tcctgacctt	5340
gggcatccg	cctgcctcag	cctcccaaag	tgctgaggtt	acaggcttga	gccactgtgc	5400
ctggcctaag	aaccaagctt	tttttttagaa	tgatagttgc	cccttcagta	gcccttcagt	5460
accatataag	ttttgctgat	gttactgggt	gttctttaat	gcattcagca	aatattaata	5520
tttactgcac	accttccatg	tgccagcccc	tggggatga	ggtgacttgt	gtttttcttt	5580
caaggagctg	acaaataagc	agcttggaact	tgaattccct	ccccttctct	tcctctcacg	5640
tctctgttga	ggcaaatccc	aattggaatg	aaataactct	ggagaattat	tttgggcgtt	5700
actaaaacta	tctttacttc	tttgctccag	aagcaacatt	agctacttag	tggcctcttg	5760
acataatcta	agaactgtct	ttgggacgtg	ctgcttctgg	gactccttgg	ctgtgaccat	5820
tttctttcaa	gtttaagtga	cttctgtctc	cttatgcatg	agtccattta	agacattctg	5880
ccaagggaga	agccatccac	tgtgggttgc	tggcttcaga	gcactctcac	tggtcagcag	5940
tccctgactc	ctatgacctc	cagtgtgtgt	tagatgatag	tttcatgaat	agcactttta	6000
acatctatgt	tgcattaggt	attataagta	atctagagat	gatttacagg	aggatgggca	6060
taggttaagt	gtaaatacca	taccatttta	tttttatatc	agtgcagtga	gcatctgcag	6120
attttggtat	ccttgggggt	ctgggaacca	atgcactgca	gatactaagg	gacaactcta	6180
cagtgtttga	tttattgagc	tttctgagat	attcagcctt	ttcctgtctt	cacacttggt	6240
tttccctcta	ttatttaggg	taatcctgat	gaaaatcaac	aaaatacaca	tgaagagaca	6300
gcactgagag	gtaatgtgct	aactggctct	tgtgattaca	ggcacttcag	atttccctct	6360
tgcctactca	ttgtgagatg	cagcccagcc	ctgcaacaag	actgccacag	tcgtatcctg	6420
gctcaccctt	aactagcggg	ttgactttga	gcacatcact	gcctcctccg	tgccctcagtt	6480
tcctcttctg	ttgaatgggg	atgatcacag	cactacctca	ccatttggtg	tgaggattaa	6540
atagattcaa	atatgtaaga	cacttacagt	aatgctttgt	acacagaagg	cactattatt	6600
ttttatataat	ccctattttt	ccttcccaac	ttcatctccc	aatatcccat	aacctgctg	6660
atttctttac	aactccccca	gacctcctgg	actaagttag	atttggaga	gtatactcag	6720
ggcagtcaag	aaggactgat	tctgctaatt	taggatttgt	caagtgggt	tagtttgaaa	6780
tatacctctg	tactcctctc	aggaaatgct	ggatagtgtg	gatttagtat	cagataatga	6840
taataatggg	ggcagactct	gatgtttcct	ccttcccttg	tgatctcagt	agtcttgtac	6900
cattcataca	tcaaagtact	tagcaactaa	caatcacgta	atatttttta	agcttttctt	6960
atgtgccag	tagtgagcca	agagtttttt	ttcctatttt	taacatacta	ttgacagctc	7020
catgagggtg	gtttatattt	tgttaaaata	atttgccatg	tcacttccc	cagtagactg	7080
tgacagtggc	atatacatct	gtgtgtgtta	ttcagtttgt	atctctagga	cttgacagag	7140
gacceaatca	agagtgggtg	ctccagaaat	tgtggacttg	atgcatttca	ccaacagcta	7200
tttactactca	ataataaagc	taattataac	tcttcttcta	gatgtacttt	tctcattgca	7260
aaaattcacc	gtcaaaattt	ttaaaaacac	taataagcaa	gaagaaggaa	gttaaaattg	7320
cactccttcc	agccctaaag	agcttaatca	acttgcttag	gaacacgcta	ctaaatggct	7380
aatctgagca	ccaaaatctg	gccatctggc	ttcagggtct	agcctcctaa	tggccgcatt	7440
ataccattga	tcccgcacca	tccaccccaa	cacacacact	cccctgcaca	aacaaattat	7500
gttagctatt	aaaaggaatt	ggaagagtgg	aaatgtgcaa	ttaaatctac	cacaaataca	7560
atgttgcaat	acgtgcaatc	tatattttta	aaatttacag	tattcagcat	tttctgtctt	7620
tcacacttgt	tcctccggtt	atttacggca	atcatgacga	aaatcaacaa	aatacagatt	7680
gagaggcagc	actgagaggt	aatgtagaaa	gggaattggc	tttgagttag	aaaaatgcga	7740
gtgtggatcc	cagctaagcc	cctagatgtg	ttaccagaga	cgagccgcaa	aacatttctc	7800
agtcttagtc	tcttgtaaaa	tagaggtaat	aagaaacact	tttcagtatt	ttgtgacatg	7860
tagaagtaag	tgatggtggc	atgcatcaca	cttggttaat	agtaggtcct	gttggttaagt	7920
ctctaattggc	gataccctat	ggcttctcca	aatggtgacc	ttgccaaatt	gttttccaaa	7980
gagacatgtg	gcttttttct	occaatccct	cattttaact	ctcatggtaa	tttaactttt	8040
atatttttat	tagatgcatt	tagtaacttg	cctcatagtc	attttcttgg	aaattcaatt	8100
tcttctccac	agggtctctt	ttgagattaa	agagagagaa	gtggcaaaat	taggatgtta	8160
gaataatttt	catttaaaaag	tagatccttg	tttttattac	cctatcatta	atgttttctg	8220
ttttctttta	tcagcgagtt	actgctcatt	tgattcatat	tgccaaactg	aactctcttg	8280
ttttcttgca	agatgaaagg	agacaaccat	gaatgagcca	ctagactatt	tagcaaatgc	8340
ttctgatttc	cccgatattg	cagctgcttt	tggaaattgc	actgatgaaa	acatcccat	8400
caagatgcac	tacctccctg	ttatttatgg	cattatcttc	ctcgtgggat	ttccaggcaa	8460
tgcagtagtg	atatccactt	acattttcaa	aatgagacct	tgggaagaca	gcaccatcat	8520
tatgctgaac	ctggcctgca	cagatctgct	tgtatctgacc	agcctcccct	tcctgattca	8580
ctactatgcc	agtggcgaaa	actggatctt	tggagatttc	atgtgtaagt	ttatccgctt	8640
cagcttccat	ttcaacctgt	atagcagcat	cctcttcttc	acctgtttca	gcatcttccg	8700

```

ctactgtgtg atcattcacc caatgagctg cttttccatt cacaaaaactc gatgtgcagt 8760
tgtagcctgt gctgtggtgt ggatcatctt actggtagct gtcattccga tgaccttctt 8820
gatcacatca accaacagga ccaacagatc agcctgtctc gacctacca gttcggatga 8880
actcaatact attaagtggg acaacctgat tttgactgca actactttct gcctcccctt 8940
ggtgatagt acactttgct ataccacgat tatccacact ctgacccatg gactgcaaac 9000
tgacagctgc ctttaagcaga aagcacgaag gctaaccatt ctgctactcc ttgcatctta 9060
cgtatgtttt ttacccttcc atatcttgag ggtcattogg atcgaatctc gcctgctttc 9120
aatcagttgt tccattgaga atcagatcca tgaagcttac atcgtttcta gaccattagc 9180
tgctctgaac accttttgta acctgttact atatgtggtg gtcagcgaca actttcagca 9240
ggctgtctgc tcaacagatg gatgcaaagt aagcggaac cttgagcaag caaagaaaat 9300
tagttactca aacaaccctt gaaatatttc atttacttaa ccaaaaacaa atactctgtg 9360
atactttacc tagcatccta agatgttcag gatgtctccc tcaatggaac tcctggtaaa 9420
tactgtgtat tcaagtaatc atgtgcaaaa gccagggcag agcttctagt tctttgcaat 9480
ccctttattg agctcctcca ctggggagat ataagaatgg gatgcatgta tatcagcaaa 9540
gtattcagac atagtattac aagctattgg aactcagagg catcttagag aacatctgtt 9600
cccaccaact tactatatat acacggaaac caatttctta cccttgccct agattgtctc 9660
gtaaatttgt gccaaagatg gagaaaacca atcttttcac tcatcatttc atgcttctct 9720
gcactctggg cctatttgta ttgaaccatt agacaattca aaccactact tgtatcttct 9780
ttaatatatta ttttttacat ctcagagctc tacaatttgt ttccttcaag cttaactttg 9840
agattataaaa actgggttta gccagttctg tatattactt caagccagta agataccctt 9900
gaaat 9905

```

<210> 4

<211> 299

<212> PRT

<213> Mus musculus

<400> 4

```

Cys Ala Leu Thr Lys Thr Gly Phe Gln Phe Tyr Tyr Leu Pro Ala Val
  1          5          10          15
Tyr Ile Leu Val Phe Ile Ile Gly Phe Leu Gly Asn Ser Val Ala Ile
  20          25          30
Trp Met Phe Val Phe His Met Lys Pro Trp Ser Gly Ile Ser Val Tyr
  35          40          45
Met Phe Asn Leu Ala Leu Ala Asp Phe Leu Tyr Val Leu Thr Leu Pro
  50          55          60
Ala Leu Ile Phe Tyr Tyr Phe Asn Lys Thr Asp Trp Ile Phe Gly Asp
  65          70          75          80
Ala Met Cys Lys Leu Gln Arg Phe Ile Phe His Val Asn Leu Tyr Gly
  85          90          95
Ser Ile Leu Phe Leu Thr Cys Ile Ser Ala His Arg Tyr Ser Gly Val
  100         105         110
Val Tyr Pro Leu Lys Ser Leu Gly Arg Leu Lys Lys Lys Asn Ala Ile
  115         120         125
Tyr Val Ser Val Leu Val Trp Leu Ile Val Val Val Ala Ile Ser Pro
  130         135         140
Ile Leu Phe Tyr Ser Gly Thr Gly Thr Arg Lys Asn Lys Thr Val Thr
  145         150         155         160
Cys Tyr Asp Thr Thr Ser Asn Asp Tyr Leu Arg Ser Tyr Phe Ile Tyr
  165         170         175
Ser Met Cys Thr Thr Val Ala Met Phe Cys Ile Pro Leu Val Leu Ile
  180         185         190
Leu Gly Cys Tyr Gly Leu Ile Val Lys Ala Leu Ile Tyr Asn Asp Leu
  195         200         205
Asp Asn Ser Pro Leu Arg Arg Lys Ser Ile Tyr Leu Val Ile Ile Val
  210         215         220
Leu Thr Val Phe Ala Val Ser Tyr Ile Pro Phe His Val Met Lys Thr
  225         230         235         240
Met Asn Leu Arg Ala Arg Leu Asp Phe Gln Thr Pro Glu Met Cys Asp
  245         250         255
Phe Asn Asp Arg Val Tyr Ala Thr Tyr Gln Val Thr Arg Gly Leu Ala
  260         265         270

```

Ser Leu Asn Ser Cys Val Asp Pro Ile Leu Tyr Phe Leu Ala Gly Asp
 275 280 285
 Thr Phe Arg Arg Arg Leu Ser Arg Ala Thr Arg
 290 295

<210> 5
 <211> 101
 <212> DNA
 <213> Human

<400> 5
 agaggcagca ctgagaggta atgtagaaag ggaatggctt ttgagtcaga maaatgcgag 60
 tgtggatccc agctaagccc ctagatgtgt taccagagac g 101

<210> 6
 <211> 101
 <212> DNA
 <213> Human

<400> 6
 cactaataag caagaagaag gaagttaaaa ttgcactcct tccagcccta ragagcttaa 60
 tcaacttgct taggaacacg ctactaaatg gctaattctga g 101

<210> 7
 <211> 101
 <212> DNA
 <213> HUMAN

<400> 7
 cttacagtaa tgctttgtac acagaaggca ctattatfff ttattaatcc ytatttttcc 60
 ttcccaactt catctcccaa tatcccataa ccatgctgat t 101

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/087980 A3

(51) International Patent Classification⁷: C07K 14/705,
C12N 15/12, C07K 16/28, A01K 67/027, A61K 38/17

(74) Agent: CELERA GENOMICS CORP.; Robert A. Millman, Patent Director, 45 West Gude Drive C2-4, Rockville, MD 20850 (US).

(21) International Application Number: PCT/US01/15957

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 17 May 2001 (17.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/205,196 18 May 2000 (18.05.2000) US
09/634,656 8 August 2000 (08.08.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: APPLERA CORPORATION [US/US];
Robert A. Millman, Assistant Secretary, 761 Main Avenue,
Norwalk, CT 06859 (US).

Published:

— with international search report

(72) Inventors: WEI, Ming-Hui; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). ZHAO, Qi; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). CRAVCHIK, Anibal; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). BEASLEY, Ellen M.; Celera, 45 West Gude Drive, Rockville, MD 20850 (US).

(88) Date of publication of the international search report:
18 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ISOLATED HUMAN G-PROTEIN COUPLED RECEPTORS, NUCLEIC ACID MOLECULES ENCODING HUMAN GPCR PROTEINS, AND USES THEREOF

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the Human genome, the GPCR peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the GPCR peptides and methods of identifying modulators of the GPCR peptides.

WO 01/087980 A3



INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 01/15957

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 C12N15/12 C07K16/28 A01K67/027 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LEON C ET AL: "Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor"</p> <p>GENE, ELSEVIER BIOMEDICAL PRESS.</p> <p>AMSTERDAM, NL,</p> <p>vol. 171, no. 2, 1 June 1996 (1996-06-01),</p> <p>pages 295-297, XP004042812</p> <p>ISSN: 0378-1119</p> <p>cited in the application</p> <p>the whole document</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1,2,4,5, 8-11,13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 March 2002

Date of mailing of the international search report

28/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 01/15957

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TOKUYAMA Y ET AL: "CLONING OF RAT AND MOUSE P2Y PURINOCEPTORS" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 211, no. 1, 6 June 1995 (1995-06-06), pages 211-218, XP000673449 ISSN: 0006-291X figure 1 ---	1,2,4,5, 8-11,13
A	WO 97 20045 A (COR THERAPEUTICS INC) 5 June 1997 (1997-06-05) page 1, line 20 -page 2, line 20; figures 1A-C; examples 1,2 ---	1,2,4,5, 8-11,13
A	VOLONTE C ET AL: "SELECTED P2 PURINOCEPTOR MODULATORS PREVENT GLUTAMATE-EVOKED CYTOTOXICITY IN CULTURED CEREBELLAR GRANULE NEURONS" JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 45, no. 2, 15 July 1996 (1996-07-15), pages 183-193, XP002048687 ISSN: 0360-4012 the whole document ---	14,17
E	WO 01 36471 A (ARENA PHARMACEUTICALS INC ;CHEN RUOPING (US); DANG HUONG T (US); L) 25 May 2001 (2001-05-25) page 113-114 abstract page 3, line 10-13 page 13, line 1 -page 14, line 7; table B example 1; table C page 34, line 7-21 ---	1-17
E	WO 01 49847 A (WHITE DAVID ;GLUCKSMANN MARIA ALEXANDRA (US); MILLENNIUM PHARM INC) 12 July 2001 (2001-07-12) abstract page 1, line 18 -page 5, line 26; figure 1 ---	1-17
E	WO 01 87937 A (INCYTE GENOMICS INC ;KALLICK DEBORAH A (US); PATTERSON CHANDRA (US) 22 November 2001 (2001-11-22) SEQ.ID.N.10 abstract page 5, line 35 -page 10, line 25 ---	1-17

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/15957

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p> DATABASE EMBL 'Online! 1 December 2001 (2001-12-01) Database accession no. Q96P68 XP002193122 G PROTEIN-COUPLED RECEPTOR. GPR80. Homo sapiens abstract ----- </p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/15957

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9720045	A	05-06-1997	US 5871963 A	16-02-1999
			AU 729875 B2	15-02-2001
			AU 1075397 A	19-06-1997
			CA 2237937 A1	05-06-1997
			EP 0868510 A2	07-10-1998
			JP 2000500658 T	25-01-2000
			WO 9720045 A2	05-06-1997
			US 6063582 A	16-05-2000
WO 0136471	A	25-05-2001	AU 1769601 A	30-05-2001
			WO 0136471 A2	25-05-2001
WO 0149847	A	12-07-2001	AU 2458101 A	16-07-2001
			WO 0149847 A2	12-07-2001
WO 0187937	A	22-11-2001	WO 0187937 A2	22-11-2001
			WO 0190359 A2	29-11-2001